<SEC-DOCUMENT>0000950170-25-066968.txt : 20250508
<SEC-HEADER>0000950170-25-066968.hdr.sgml : 20250508
<ACCEPTANCE-DATETIME>20250508161300
ACCESSION NUMBER:		0000950170-25-066968
CONFORMED SUBMISSION TYPE:	S-3/A
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20250508
DATE AS OF CHANGE:		20250508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-285327
		FILM NUMBER:		25926242

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3/A
<SEQUENCE>1
<FILENAME>crdf_s-3a_5.8.25.htm
<DESCRIPTION>S-3/A
<TEXT>
<html>
 <head>
  <title>S-3/A</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As filed with the U.S. Securities and Exchange Commission on May 8, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration No. 333-285327</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:5.05pt;word-break:break-word;white-space:pre-wrap;">
     <td style="border-top:2pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, DC 20549</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:49.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="border-top:1pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment No. 1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM S-3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REGISTRATION STATEMENT</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNDER</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE SECURITIES ACT OF 1933</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:49.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="border-top:1pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Cardiff Oncology, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:40.62%;box-sizing:content-box;"></td>
     <td style="width:18.76%;box-sizing:content-box;"></td>
     <td style="width:40.62%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">27-2004382</font></p></td>
    </tr>
    <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(State or other jurisdiction</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IRS Employer</font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">of incorporation or organization)</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Identification No.)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11055 Flintkote Avenue</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, CA 92121</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(858) 952-7570</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Address, including zip code, and telephone number, including area code, of registrant&#x2019;s principal executive offices)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mark Erlander, Ph.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cardiff Oncology, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11055 Flintkote Avenue</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, CA 92121</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(858) 952-7570</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Name, address including zip code, and telephone number, including area code, of agent for service)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With copies to:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jeffrey J. Fessler, Esq.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sheppard, Mullin, Richter &amp; Hampton LLP</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30 Rockefeller Plaza</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, NY 10112</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tel: (212) 653-8700</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fax: (212) 653-8701</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:49.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="border-top:1pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approximate date of commencement of proposed sale to the public: From time to time, after the effective date of this registration statement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">o</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&yacute;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">o</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Act registration statement number of the earlier effective registration statement for the same offering. </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">o</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">o</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.59in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">o</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company&#x201d; and &#34;emerging growth company&#34; in Rule 12b-2 of the Exchange Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:45.611%;box-sizing:content-box;"></td>
     <td style="width:8.778%;box-sizing:content-box;"></td>
     <td style="width:45.611%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer </font><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">o</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer </font><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">o</font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer  </font><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&yacute;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company </font><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&yacute;</font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company </font><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">o</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">o</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until this Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.59in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PROSPECTUS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXPLANATORY NOTE</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This registration statement contains two prospectuses:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a base prospectus which covers the offering, issuance and sale by us of up to $400 million in the aggregate of the securities identified above from time to time in one or more offerings; and</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $150 million of our common stock that may be offered and sold under an Open Market Sale Agreement with Jefferies LLC.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The specific terms of the securities to be issued and sold under the Sales Agreement are specified in the sales agreement prospectus that immediately follows the base prospectus.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ff4040;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in this prospectus is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ff4040;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRELIMINARY PROSPECTUS</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ff4040;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to completion, dated May 8, 2025</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><img src="img83777979_0.jpg" alt="img83777979_0.jpg" style="width:200px;height:53px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preferred Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt Securities</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Units</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities, having an aggregate initial offering price not exceeding $400 million.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus provides a general description of the securities we may offer.  Each time we sell a particular class or series of securities, we will provide specific terms of the securities offered in a supplement to this prospectus.  The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. You should read carefully this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference herein or therein before you invest in any of our securities.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The specific terms of any securities to be offered, and the specific manner in which they may be offered, will be described in one or more supplements to this prospectus. This prospectus may not be used to consummate sales of any of these securities unless it is accompanied by a prospectus supplement. Before investing, you should carefully read this prospectus and any related prospectus supplement.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"> <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is presently listed on The Nasdaq Capital Market under the symbol &#x201c;CRDF.&#x201d; On May 5, 2025 the last reported sale price of our common stock was $2.68 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on The Nasdaq Capital Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.  Prospective purchasers of our securities are urged to obtain current information as to the market prices of our securities, where applicable.</font></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These securities may be sold directly by us, through dealers or agents designated from time to time, to or through underwriters, dealers, or through a combination of these methods on a continuous or delayed basis.  See &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan of Distribution</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; in this prospectus. We may also describe the plan of distribution for any particular offering of our securities in a prospectus supplement. If any agents, underwriters or dealers are involved in the sale of any securities in respect of which this prospectus is being delivered, we will disclose their names and the nature of our arrangements with them in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from any such sale will also be included in a prospectus supplement.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investing in our securities involves various risks.  See &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; contained herein for more information on these risks. Additional risks will be described in the related prospectus supplements under the heading &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; You should review that section of the related prospectus supplements for a discussion of matters that investors in our securities should consider.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus or any accompanying prospectus supplement.  Any representation to the contrary is a criminal offense.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The date of this prospectus is            , 2025.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section3"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:86.96%;box-sizing:content-box;"></td>
     <td style="width:3.66%;box-sizing:content-box;"></td>
     <td style="width:9.38%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section4"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ABOUT THIS PROSPECTUS</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section5"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SUMMARY</font></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">5</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section6"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">RISK FACTORS</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">11</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section7"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">11</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section8"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">USE OF PROCEEDS</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">12</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section9"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">DESCRIPTION OF CAPITAL STOCK</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">12</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section10"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">DESCRIPTION OF DEBT SECURITIES</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">14</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section11"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">DESCRIPTION OF WARRANTS</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">21</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section12"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">DESCRIPTION OF UNITS</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">23</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section13"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">LEGAL OWNERSHIP OF SECURITIES</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">24</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section14"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PLAN OF DISTRIBUTION</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">28</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#legalmatters1"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">LEGAL MATTERS</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">31</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section16"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">EXPERTS</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">31</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section17"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">WHERE YOU CAN FIND MORE INFORMATION</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">32</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section18"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">INCORPORATION OF DOCUMENTS BY REFERENCE</font></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">33</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section4"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ABOUT THIS PROSPECTUS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or SEC, using a &#x201c;shelf&#x201d; registration process. Under this shelf registration statement, we may sell from time to time in one or more offerings of common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or as units comprised of a combination of one or more of the other securities in one or more offerings up to a total dollar amount of $400 million. This prospectus provides you with a general description of the securities we may offer. Each time we sell any type or series of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits.  We may add, update or change, in a prospectus supplement or free writing prospectus, any of the information contained in this prospectus or in the documents we have incorporated by reference into this prospectus. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. This prospectus, together with the applicable prospectus supplement, any related free writing prospectus and the documents incorporated by reference into this prospectus and the applicable prospectus supplement, will include all material information relating to the applicable offering. You should carefully read both this prospectus and the applicable prospectus supplement and any related free writing prospectus, together with the additional information described under &#x201c;Where You Can Find More Information,&#x201d; before buying any of the securities being offered.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any accompanying prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or an accompanying prospectus supplement, or any related free writing prospectus that we may authorize to be provided to you. This prospectus, the accompanying prospectus supplement and any related free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, the accompanying prospectus supplement or any related free writing prospectus, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference (as our business, financial condition, results of operations and prospects may have changed since that date), even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered or securities are sold on a later date.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus may not be used to consummate sales of our securities, unless it is accompanied by a prospectus supplement. To the extent there are inconsistencies between any prospectus supplement, this prospectus and any documents incorporated by reference, the document with the most recent date will control.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As permitted by the rules and regulations of the SEC, the registration statement, of which this prospectus forms a part, includes additional information not contained in this prospectus. You may read the registration statement and the other reports we file with the SEC at the SEC&#x2019;s web site or at the SEC&#x2019;s offices described below under the heading &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Where You Can Find More Information.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company References</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this prospectus &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to Cardiff Oncology, Inc., a Delaware corporation, and its subsidiaries, unless the context otherwise requires.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section5"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUMMARY</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care (&#34;SoC&#34;) therapeutics. We are focusing our clinical program in indications such as RAS-mutated metastatic colorectal cancer (&#34;mCRC&#34;), as well as in investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma (&#34;mPDAC&#34;), small cell lung cancer (&#34;SCLC&#34;), and triple negative breast cancer (&#34;TNBC&#34;). Our clinical development programs incorporate tumor genomics and biomarker assays to refine assessment of patient response to treatment.</font></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Lead Drug Candidate, Onvansertib</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Onvansertib is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe the attributes of onvansertib described below, as well as early clinical evidence of favorable safety and efficacy, with expected on-target, manageable and tolerable side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Onvansertib is highly potent and highly selective against the PLK1 enzyme (IC</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> = 2nM; IC</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is the concentration for 50% inhibition), compared to prior PLK1 inhibitors that were pan-inhibitors of several PLK targets.  Low or no activity of onvansertib was observed on a panel of 63 kinases (IC50&gt;500 nM), including the PLK members PLK2 and PLK3 (IC</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&gt;10,000 nM);</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Onvansertib is orally bioavailable, allowing for relative ease and flexibility of dosing;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Onvansertib has a relatively short drug half-life of 24 hours, allowing for flexible dosing and scheduling that has demonstrated a favorable safety profile across multiple clinical trials.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In vitro</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> studies have shown synergistic effects when onvansertib was administered in combination with different cytotoxic agents including microtubule-targeting agents, topoisomerase 1 inhibitors, antimetabolites, alkylating agents, proteasome inhibitors, kinase inhibitors, PARP inhibitors, BCL-2 inhibitors, and androgen biosynthesis inhibitors.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> combination studies have confirmed the positive results obtained </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and additive or synergistic effects on efficacy have been observed in xenograft models of onvansertib in combination with irinotecan, 5-fluorouracil (&#34;5-FU&#34;), abiraterone, PARP inhibitors, venetoclax, paclitaxel, or bevacizumab. Combining onvansertib with SoC cancer agents may provide opportunities for synergy with many cancer therapies.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are several ongoing and planned clinical trials of onvansertib in multiple indications: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAS-mutated mCRC Program:</font></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRDF-004 Randomized Clinical Trial in First-Line RAS-mutated mCRC</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRDF-004 is a Phase 2 open-label, randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC. The primary objectives of the CRDF-004 trial are to evaluate onvansertib&#x2019;s safety and efficacy in combination with the SoC, as well as to evaluate two doses of onvansertib, 20mg and 30mg, given in combination with SoC, against SoC alone. The primary endpoint of the trial is objective response rate (&#34;ORR&#34;). Progression-free survival and duration of response will be secondary endpoints.  This trial is conducted in partnership with Pfizer Ignite, an end-to-end service for biotech companies, and it is expected to enroll approximately 90 evaluable patients. For more information, please visit NCT06106308 at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicialtrials.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingent upon the results of CRDF-004, we plan to initiate CRDF-005, a Phase 3, randomized trial with registrational intent. The FDA has agreed that a seamless trial with an interim endpoint of ORR, with duration of response, is acceptable to pursue accelerated approval, with progression-free survival and trend in overall survival being the endpoints for full approval.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data presented on December 10, 2024 provided initial results from the ongoing CRDF-004 Phase 2 randomized clinical trial in first-line RAS-mutated metastatic colorectal cancer. ORR, as of the data cut-off date of November 26, 2024, are shown below.</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:24.07%;box-sizing:content-box;"></td>
     <td style="width:1.24%;box-sizing:content-box;"></td>
     <td style="width:24.07%;box-sizing:content-box;"></td>
     <td style="width:1.24%;box-sizing:content-box;"></td>
     <td style="width:24.07%;box-sizing:content-box;"></td>
     <td style="width:1.24%;box-sizing:content-box;"></td>
     <td style="width:24.07%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Control Arm (SoC alone)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">20mg dose of onvansertib + SoC</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">30mg dose of onvansertib + SoC</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All onvansertib patients</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33% ORR<br>(3 of 9)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50% ORR<br>(5 of 10)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64% ORR<br>(7 of 11)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57% ORR<br>(12 of 21)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Spider Plots, displaying the change in tumor size from baseline for each patient over time, demonstrate deeper responses observed in patients receiving the 30mg dose of onvansertib in combination with the SoC compared to both the control arms and 20mg dose of onvansertib arms.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img83777979_1.jpg" alt="img83777979_1.jpg" style="width:602px;height:326px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note: Radiographic response determined per RECIST 1.1 by blinded independent central review. Spider plot reflects interim data as of November 26, 2024 from an ongoing trial and unlocked database.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Onvansertib in combination with chemo/bevacizumab was well-tolerated and there have been no major or unexpected toxicities observed.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1b/2 Clinical Trial in Second-Line KRAS-mutated mCRC</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC, completed enrollment in October 2022.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary objectives of this trial were to evaluate the Dose-Limiting Toxicities (&#34;DLTs&#34;), maximum tolerated dose (&#34;MTD&#34;) and recommended Phase 2 dose (&#34;RP2D&#34;) of onvansertib in combination with FOLFIRI and bevacizumab (Phase 1b) and to continue to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab patients with KRAS-mutated mCRC (Phase 2). For more information, please visit NCT03829410 at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicialtrials.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data presented on August 7, 2023, provided an update of the ongoing TROV-054 Phase 1b/2 single arm clinical trial in KRAS-mutated metastatic colorectal cancer:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ORR across all evaluable patients was 29%, with 19 of 66 evaluable patients achieving an objective response. Responses have been observed across multiple KRAS variants;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Median duration of response (&#34;mDoR&#34;) across all evaluable patients was 12.0 months (95% confidence interval (&#34;CI&#34;): 8.9 &#x2013; not reached);</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Median progression free survival (&#34;mPFS&#34;) across all evaluable patients was 9.3 months (95% CI: 7.8 &#x2013; 14). Historical control trials of different drug combinations, including the SoC of FOLFIRI with bevacizumab, in similar patient populations have shown ORR and mPFS of 5 &#x2013; 13% and ~4.5 &#x2013; 6.7 months, respectively;</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A subgroup analysis of patients who were bevacizumab na&iuml;ve when they entered second-line therapy vs. patients who had received prior bevacizumab in first-line therapy showed that patients who were bevacizumab na&iuml;ve (n=15) had an ORR of 73% and mPFS of 15 months, which is well above historical controls. In contrast, patients previously treated with bevacizumab (n=51) had an ORR of 16% and mPFS of 7.8 months;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data on Treatment Emergent Adverse Events (&#34;TEAEs&#34;) on the trial showed that onvansertib is well-tolerated when used in combination with FOLFIRI and bevacizumab.  The more severe, grade 4 TEAEs are either neutropenia or leukopenia, which are common events in patients treated with FOLFIRI and bevacizumab. None of the patients with grade 4 TEAEs discontinued treatment due to their condition and all resolved without issue. There were no major or unexpected toxicities seen in the trial;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data from the Phase 1b portion of this trial was published in the peer-reviewed journal Clinical Cancer Research, February 6, 2024 edition; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data from the Phase 2 portion of this trial was published online in the peer-reviewed journal of Clinical Oncology on October 30, 2024. </font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the interim results of the TROV-054 trial, we designed the ONSEMBLE trial (CRDF-003) as the next phase of our mCRC program.  Upon further review of the clinical data from the bevacizumab na&iuml;ve subgroup (those patients who did not receive bevacizumab in their first-line therapy), the preclinical data on the mechanism of action and the feedback from the FDA on our clinical development strategy, we made the decision to discontinue enrollment in the ONSEMBLE trial and to initiate the CRDF-004 clinical trial.</font></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2 Clinical Trial in Second-Line RAS-mutated mCRC</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ONSEMBLE trial (CRDF-003) was a Phase 2 randomized, open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with RAS-mutated mCRC. The ONSEMBLE trial completed enrollment in August 2023 as part of our shift to a first-line mCRC program. The primary objectives of the ONSEMBLE trial were to evaluate onvansertib&#x2019;s safety and efficacy in combination with FOLFIRI and bevacizumab, as well as to evaluate two doses of onvansertib, 20mg and 30mg, given in combination with FOLFIRI and bevacizumab, against FOLFIRI and bevacizumab alone. The primary endpoint of the trial was ORR. For more information, please visit NCT05593328 at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicialtrials.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ORR data from the randomized ONSEMBLE trial validates the findings observed in our earlier single-arm Phase 1b/2 KRAS-mutated mCRC trial (TROV-054). In the ONSEMBLE trial, objective responses were observed only in bevacizumab na&iuml;ve patients, not bevacizumab exposed patients. In addition, these objective responses were present only in bevacizumab na&iuml;ve patients randomized to the experimental arms of onvansertib in combination with FOLFIRI and bevacizumab versus bevacizumab na&iuml;ve patients randomized to the FOLFIRI and bevacizumab alone control arm.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mPDAC Program:</font></p><p style="margin-left:4.533%;text-indent:2.235%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1b/2 Investigator-Initiated Clinical Trial in First-Line mPDAC</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the FDA approved NALIRIFOX as a first-line treatment option for mPDAC. As a result, we are currently supporting a new investigator-initiated mPDAC Phase 1b/2 trial of onvansertib in combination with first-line SoC NALIRIFOX, which is now open for enrollment at the University of Kansas Medical Center. The trial replaced a previously planned two-cohort, non-randomized Phase 2 trial of onvansertib in combination with first-line SoC Gemzar</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Abraxane</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> .  For more information, please visit NCT06736717 at</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> www.clinicaltrials.gov.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary objective in this study is to determine anti-tumor activity by measuring Overall Response Rate (ORR). The secondary objectives are to determine treatment safety based on toxicities in participants who have received at least one dose of onvansertib, to determine anti-tumor activity by Progression Free Survival (PFS), to determine anti-tumor activity by Disease Control Rate (DCR), to determine Overall Survival (OS).</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2 Clinical Trial in mPDAC</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan (Onivyde</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), leucovorin, and fluorouracil for 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> line treatment of patients with mPDAC, completed enrollment in October 2023.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The objective of this trial was to assess the safety and preliminary efficacy of onvansertib in combination with nanoliposomal irinotecan (Onyvide</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), 5-FU and leucovorin as a 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> line treatment in patients with mPDAC who have failed first-line gemcitabine-based therapy. For more information, please visit NCT04752696 at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicialtrials.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preliminary data presented on September 26, 2023, and updated on February 29, 2024, showed promising data that caused us to shift the program to a first-line investigator initiated trial.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mPDAC biomarker discovery trial</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The investigator-initiated biomarker discovery trial is exploring the impact of onvansertib 10-day monotherapy on tumors in mPDAC patients, and enrolled at the Oregon Health &amp; Science University (OHSU) Knight Cancer Institute. Enrollment for this trial is closed.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preliminary data were presented on September 26, 2023. One patient demonstrated an 86% decrease in Ki67, a well-established biomarker of tumor proliferation, and a 28% decrease in CA 19-9, a clinically-used biomarker to monitor treatment response.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Clinical Programs:</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2 Investigator-Initiated Clinical Trial in SCLC</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A single-arm, two-stage, Phase 2 trial of onvansertib monotherapy in patients with relapsed SCLC is open for enrollment at the University of Maryland, Baltimore. The trial is designed to enroll 15 patients in Stage 1, with the study proceeding to Stage 2 if 2 or more Stage 1 patients achieve an objective response. Stage 2 is designed to enroll an additional 20 patients. The primary endpoint of the trial is ORR, while key secondary endpoints include PFS and overall survival. For more information, please visit NCT05450965 at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicialtrials.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An examination of the safety data from the first six patients by the institutional review board confirmed the trial can continue to enroll as planned. Preliminary efficacy data for seven patients presented on September 26, 2023, showed one confirmed partial response (&#x201c;PR&#x201d;), three stable disease (&#x201c;SD&#x201d;) and three progressive disease (&#x201c;PD&#x201d;). The disease control rate (&#x201c;DCR&#x201d;), including PR and SD, is 57% (4 of 7 patients).</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1b Investigator-Initiated Clinical Trial in TNBC</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A single-arm, Phase 1b trial of onvansertib in combination with paclitaxel in patients with unresectable locally advanced or metastatic TNBC is open for enrollment at Dana Farber Cancer Institute (&#34;DFCI&#34;). In Phase 1b, approximately 14-16 patients will be treated with different doses of onvansertib in combination with a fixed dose of paclitaxel to determine the maximum tolerated dose and the safety and efficacy of onvansertib in combination with paclitaxel. For more information, please visit NCT05383196 at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicialtrials.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Associated with Our Business</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to raise substantial additional capital to develop and commercialize, our product candidate, onvansertib, and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidate is in the early stages of clinical development and its commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our product candidate, our business will be materially harmed.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the results of preclinical studies or clinical trials for our product candidate, including those that are subject to existing or future license or collaboration agreements, are unfavorable or delayed, we could be delayed or precluded from the further development or commercialization of our product candidate, which could materially harm our business.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If third party vendors upon whom we intend to rely on to conduct our preclinical studies or clinical trials do not perform or fail to comply with strict regulations, these studies or trials of our product candidate may be delayed, terminated, or fail, or we could incur significant additional expenses, which could materially harm our business.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, and our collaborators, must comply with extensive government regulations in order to advance our product candidate through the development process and ultimately obtain and maintain marketing approval for our products in the U.S. and abroad.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience in the development of therapeutic product candidates and therefore may encounter difficulties developing our product candidate or managing our operations in the future.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays in clinical testing could result in increased costs to us and delay our ability to generate revenue.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidate, our business will be substantially harmed.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security threats to our information technology infrastructure and/or our physical buildings could expose us to liability and damage our reputation and business.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the manufacturers upon whom we rely fail to produce our product candidate, in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of our product candidate.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidate, if approved for sale, may not gain acceptance among physicians, patients and the medical community, thereby limiting our potential to generate revenues.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we materially breach or default under the Nerviano Licensing Agreement, Nerviano will have the right to terminate the agreement and we could lose critical license rights, which would materially harm our business.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2013;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.</font></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Information</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were originally incorporated under the laws of the State of Florida in April 2002. In January 2010, we re-incorporated under the laws of the State of Delaware and changed our name to Trovagene, Inc. In May 2012, our common stock was listed on The Nasdaq Capital Market (&#34;Nasdaq&#34;) under the ticker symbol TROV. In May 2020 we changed our name to Cardiff Oncology, Inc. and our Nasdaq ticker symbol changed to CRDF. Our corporate website address is </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.cardiffoncology.com</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Securities We May Offer</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may offer shares of our common stock and preferred stock, various series of debt securities and warrants to purchase any of such securities, either individually or in units, from time to time under this prospectus, together with any applicable prospectus supplement and related free writing prospectus, at prices and on terms to be determined by market conditions at the time of offering. If we issue any debt securities at a discount from their original stated principal amount, then, for purposes of calculating the total dollar amount of all securities issued under this prospectus, we will treat the initial offering price of the debt securities as the total original principal amount of the debt securities. Each time we offer securities under this prospectus, we will provide offerees with a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities being offered, including, to the extent applicable:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">designation or classification;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">aggregate principal amount or aggregate offering price;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maturity, if applicable;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">original issue discount, if any;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rates and times of payment of interest or dividends, if any;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">redemption, conversion, exchange or sinking fund terms, if any;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ranking;</font></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictive covenants, if any;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">voting or other rights, if any; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">important United States federal income tax considerations.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update, or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may sell the securities to or through underwriters, dealers or agents or directly to purchasers. We, as well as any agents acting on our behalf, reserve the sole right to accept and to reject in whole or in part any proposed purchase of securities. Each prospectus supplement will set forth the names of any underwriters, dealers or agents involved in the sale of securities described in that prospectus supplement and any applicable fee, commission or discount arrangements with them, details regarding any over-allotment option granted to them, and net proceeds to us. The following is a summary of the securities we may offer with this prospectus.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have authorized 150,000,000 shares of common stock, par value $0.0001 per share. As of May 5, 2025, 66,525,854 shares of common stock were issued and outstanding. We may offer shares of our common stock either alone or underlying other registered securities convertible into or exercisable for our common stock. Holders of our common stock are entitled to such dividends as our board of directors (the &#x201c;Board of Directors&#x201d; or &#x201c;Board&#x201d;) may declare from time to time out of legally available funds, subject to the preferential rights of the holders of any shares of our preferred stock that are outstanding or that we may issue in the future. Currently, we do not pay any dividends on our common stock. Each holder of our common stock is entitled to one vote per share. In this prospectus, we provide a general description of, among other things, the rights and restrictions that apply to holders of our common stock.</font></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preferred Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have authorized 20,000,000 shares of preferred stock, par value $0.001, of which 277,100 shares are designated as Series A Convertible Preferred Stock, of which 60,600 shares are issued and outstanding as of May 5, 2025;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any authorized and undesignated shares of preferred stock may be issued from time to time in one or more additional series pursuant to a resolution or resolutions providing for such issue duly adopted by our Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly unissued series of preferred stock, including without limitation authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rights, preferences, privileges, and restrictions granted to or imposed upon any series of preferred stock that we offer and sell under this prospectus and applicable prospectus supplements will be set forth in a certificate of designation relating to the series. We will incorporate by reference into the registration statement of which this prospectus is a part the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of shares of that series of preferred stock. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt Securities</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may offer general debt obligations, which may be secured or unsecured, senior or subordinated, and convertible into shares of our common stock or preferred stock. In this prospectus, we refer to the senior debt securities and the subordinated debt securities together as the &#x201c;debt securities.&#x201d; We may issue debt securities under a note purchase agreement or under an indenture to be entered between us and a trustee. The indentures do not limit the amount of securities that may be issued under it and provide that debt securities may be issued in one or more series. The senior debt securities will have the same rank as all of our other indebtedness that is not subordinated. The subordinated debt securities will be subordinated to our senior debt on terms set forth in the applicable prospectus supplement. In addition, the subordinated debt securities will be effectively subordinated to</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">creditors and preferred stockholders of our subsidiaries. Our Board of Directors will determine the terms of each series of debt securities being offered. This prospectus contains only general terms and provisions of the debt securities. The applicable prospectus supplement will describe the particular terms of the debt securities offered thereby. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of debt securities being offered, as well as the complete note agreements and/or indentures that contain the terms of the debt securities. The forms of senior and subordinated indentures have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of debt securities being offered will be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may offer warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue the warrants by themselves or together with common stock, preferred stock or debt securities, and the warrants may be attached to or separate from any offered securities. Any warrants issued under this prospectus may be evidenced by warrant certificates.  Warrants may be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent. Our Board of Directors will determine the terms of the warrants. This prospectus contains only general terms and provisions of the warrants. The applicable prospectus supplement will describe the particular terms of the warrants being offered thereby. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of warrants being offered, as well as the complete warrant agreements that contain the terms of the warrants. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Units</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may offer units consisting of our common stock or preferred stock, debt securities and/or warrants to purchase any of these securities in one or more series. We may evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus supplement relating to a particular series of units. This prospectus contains only a summary of certain general features of the units. The applicable prospectus supplement will describe the particular features of the units being offered thereby. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and will be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section6"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISK FACTORS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An investment in our securities involves a high degree of risk. This prospectus contains, and the prospectus supplement applicable to each offering of our securities will contain, a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading &#x201c;Risk Factors&#x201d; in this prospectus and the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under Item 1A, &#x201c;Risk Factors,&#x201d; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 27, 2025, and any updates described in our Quarterly Reports on Form 10-Q, all of which are incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future and any prospectus supplement related to a particular offering. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these known or unknown risks might cause you to lose all or part of your investment in the offered securities.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section7"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus, any accompanying prospectus supplement, any related free writing prospectus and the documents incorporated by reference herein or therein contain, in addition to historical information, certain forward-looking statements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">within the meaning of Section 27A of the Securities Act or 1933, as amended (the &#x201c;Securities Act&#x201d;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), that include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation and availability of resources. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, you can identify forward-looking statements by terminology, such as &#x201c;expects,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;intends,&#x201d; &#x201c;estimates,&#x201d; &#x201c;plans,&#x201d; &#x201c;believes,&#x201d; &#x201c;seeks,&#x201d; &#x201c;may,&#x201d; &#x201c;should&#x201d;, &#x201c;could&#x201d; or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus supplement or incorporated herein by reference.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from those expressed or implied in our written or oral forward-looking statements may be found in this prospectus supplement under the heading &#x201c;Risk Factors&#x201d; and in our Annual Report on Form 10-K for the year ended December 31, 2024 under the headings &#x201c;Risk Factors&#x201d; and &#x201c;Business,&#x201d; as updated in our Quarterly Report(s) on Form 10-Q.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-looking statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this prospectus supplement and incorporated herein by reference, and particularly our forward-looking statements, by these cautionary statements.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section8"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">USE OF PROCEEDS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as described in any prospectus supplement and any free writing prospectus in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered under this prospectus for general corporate purposes, including the development and commercialization of our products, research and development, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures. We may also use the net proceeds to repay any debts and/or invest in or acquire complementary businesses, products, or technologies, although we have no current commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus. We have not determined the amount of net proceeds to be used specifically for the foregoing purposes. As a result, our management will have broad discretion in the allocation of the net proceeds and investors will be relying on the judgment of our management regarding the application of the proceeds of any sale of the securities. Pending use of the net proceeds, we intend to invest the proceeds in short-term, investment-grade, interest-bearing instruments.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each time we offer securities under this prospectus, we will describe the intended use of the net proceeds from that offering in the applicable prospectus supplement. The actual amount of net proceeds we spend on a particular use will depend on many factors, including, our future capital expenditures, the amount of cash required by our operations, and our future revenue growth, if any. Therefore, we will retain broad discretion in the use of the net proceeds.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section9"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF CAPITAL STOCK</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following description of our capital stock, together with any additional information we include in any applicable prospectus supplement or any related free writing prospectus, summarizes the material terms and provisions of our common stock and the preferred stock that we may offer under this prospectus. While the terms we have summarized below will apply generally to any future common stock or preferred stock that we may offer, we will describe the particular terms of any class or series of</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">these securities in more detail in the applicable prospectus supplement. For the complete terms of our common stock and preferred stock, please refer to our amended and restated certificate of incorporation, as amended (&#x201c;Certificate of Incorporation&#x201d;), and our bylaws that are incorporated by reference into the registration statement of which this prospectus is a part or may be incorporated by reference in this prospectus or any applicable prospectus supplement. The terms of these securities may also be affected by Delaware General Corporation Law (the &#x201c;DGCL&#x201d;). The summary below and that contained in any applicable prospectus supplement or any related free writing prospectus are qualified in their entirety by reference to our Certificate of Incorporation and our bylaws.</font></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date of this prospectus, our authorized capital stock consisted of 150,000,000 shares of common stock, $0.0001 par value per share, and 20,000,000 shares of preferred stock, $0.001 par value per share. Our Board may establish the rights and preferences of the preferred stock from time to time. As of May 5, 2025, there were 66,525,854 shares of our common stock issued and outstanding, 60,600 shares of our Series A Convertible Preferred Stock issued and outstanding.</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are authorized to issue up to a total of 150,000,000 shares of common stock, par value $0.0001 per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common stock have no cumulative voting rights. All shares of common stock offered hereby will, when issued, be fully paid and nonassessable, including shares of common stock issued upon the exercise of common stock warrants or subscription rights, if any.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, holders of our common stock have no preemptive or conversion rights or other subscription rights. Upon our liquidation, dissolution or winding- up, holders of our common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation preferences of any of our outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our Board of Directors out of our assets which are legally available. Such dividends, if any, are payable in cash, in property or in shares of capital stock.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of a majority of the shares of our capital stock, represented in person or by proxy, are necessary to constitute a quorum for the transaction of business at any meeting. If a quorum is present, an action by stockholders entitled to vote on a matter is approved if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action, with the exception of the election of directors, which requires a plurality of the votes cast.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preferred Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors has the authority, without further action by the stockholders, to issue up to 20,000,000 shares of preferred stock in one or more series and to fix the designations, powers, preferences, privileges, and relative participating, optional, or special rights as well as the qualifications, limitations, or restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, any or all of which may be greater than the rights of the common stock. Our Board of Directors, without stockholder approval, can issue preferred stock with voting, conversion, or other rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued quickly with terms calculated to delay or prevent a change of control or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock, and may adversely affect the voting and other rights of the holders of common stock. At present, we have no plans to issue any shares of preferred stock following this offering.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Takeover Effects of Certain Provisions of our Certificate of Incorporation, Bylaws and the DGCL</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are governed by the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly traded Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A business combination includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. An interested stockholder is a person who, together with affiliates and associates, owns (or within three years, did own) 15% or more of the corporation&#x2019;s voting stock, subject to certain exceptions. The statute could have the effect of delaying, deferring or preventing a change in control of our Company.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Certificate of Incorporation and bylaws contain provisions that could have the effect of discouraging potential acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. In particular, our Certificate of Incorporation and bylaws, as applicable, among other things:</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide our Board of Directors with the ability to alter our bylaws without stockholder approval; and</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that vacancies on our Board of Directors may be filled by a majority of directors in office, although less than a quorum.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such provisions may have the effect of discouraging a third-party from acquiring us, even if doing so would be beneficial to our stockholders. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our Board of Directors and in the policies formulated by them, and to discourage some types of transactions that may involve an actual or threatened change in control of our Company. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage some tactics that may be used in proxy fights. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our Company outweigh the disadvantages of discouraging such proposals because, among other things, negotiation of such proposals could result in an improvement of their terms.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, these provisions could have the effect of discouraging others from making tender offers for our shares that could result from actual or rumored takeover attempts. These provisions also may have the effect of preventing changes in our management.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:0.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Listing</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is listed on The Nasdaq Capital Market under the trading symbol &#x201c;CRDF.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:0.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer Agent and Registrar</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Transfer Agent and Registrar for our common stock is Pacific Stock Transfer Company, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section10"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF DEBT SECURITIES</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following description, together with the additional information we include in any applicable prospectus supplements or free writing prospectuses, summarizes the material terms and provisions of the debt securities that we may offer under this prospectus. We may issue debt securities, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any future debt securities we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement or free writing prospectus. The terms of any debt securities we offer under a prospectus supplement may differ from the terms we describe below. However, no prospectus supplement shall fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. As of the date of this prospectus, we have no outstanding registered debt securities. Unless the context requires otherwise, whenever we refer to the &#x201c;indentures,&#x201d; we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will issue any senior debt securities under the senior indenture that we will enter into with the trustee named in the senior indenture. We will issue any subordinated debt securities under the subordinated indenture and any supplemental indentures that we will enter into with the trustee named in the subordinated indenture. We have filed forms of these documents as exhibits to the registration statement, of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The indentures will be qualified under the Trust Indenture Act of 1939, as amended (the &#x201c;Trust Indenture Act&#x201d;). We use the term &#x201c;trustee&#x201d; to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and qualified in their entirety by reference to, all of the provisions of the indenture and any supplemental indentures applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indentures that contains the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior indenture and the subordinated indenture are identical.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of each series of debt securities will be established by or pursuant to a resolution of our Board of Directors and set forth or determined in the manner provided in an officers&#x2019; certificate or by a supplemental indenture. Debt securities may be issued in separate series without limitation as to aggregate principal amount. We may specify a maximum aggregate principal amount for the debt securities of any series. We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including:</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the title;</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the principal amount being offered, and if a series, the total amount authorized and the total amount outstanding;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any limit on the amount that may be issued;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether or not we will issue the series of debt securities in global form, and, if so, the terms and who the depositary will be;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the maturity date;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a United States person for tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of the subordination of any series of subordinated debt;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the place where payments will be made;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on transfer, sale or other assignment, if any;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right, if any, to defer payment of interest and the maximum length of any such deferral period;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provisions for a sinking fund purchase or other analogous fund, if any, including the date, if any, on which, and the price at which we are obligated, pursuant thereto or otherwise, to redeem, or at the holder&#x2019;s option, to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the indenture will restrict our ability or the ability of our subsidiaries, if any, to:</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:20%;text-indent:5.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.32875%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur additional indebtedness;</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:20%;text-indent:5.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.32875%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue additional securities;</font></div></div><p style="margin-left:16.667%;text-indent:5.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:20%;text-indent:5.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.32875%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">create liens;</font></div></div><p style="margin-left:16.667%;text-indent:5.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:20%;text-indent:5.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.32875%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pay dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries;</font></div></div><p style="margin-left:16.667%;text-indent:5.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:20%;text-indent:5.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.32875%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">redeem capital stock;</font></div></div><p style="margin-left:16.667%;text-indent:5.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:20%;text-indent:5.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.32875%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">place restrictions on our subsidiaries&#x2019; ability to pay dividends, make distributions or transfer assets;</font></div></div><p style="margin-left:16.667%;text-indent:5.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:20%;text-indent:5.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.32875%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">make investments or other restricted payments;</font></div></div><p style="margin-left:16.667%;text-indent:5.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:20%;text-indent:5.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.32875%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sell or otherwise dispose of assets;</font></div></div><p style="margin-left:16.667%;text-indent:5.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:20%;text-indent:5.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.32875%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enter into sale-leaseback transactions;</font></div></div><p style="margin-left:16.667%;text-indent:5.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:20%;text-indent:5.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.32875%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage in transactions with stockholders or affiliates;</font></div></div><p style="margin-left:16.667%;text-indent:5.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:20%;text-indent:5.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.32875%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue or sell stock of our subsidiaries; or</font></div></div><p style="margin-left:16.667%;text-indent:5.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:20%;text-indent:5.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.32875%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effect a consolidation or merger;</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a discussion of certain material or special United States federal income tax considerations applicable to the debt securities;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information describing any book-entry features;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the applicability of the provisions in the indenture on discharge;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the debt securities are to be offered at a price such that they will be deemed to be offered at an &#x201c;original issue discount&#x201d; as defined in paragraph (a) of Section 1273 of the Internal Revenue Code of 1986, as amended;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; and</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the debt securities, and any terms that may be required by us or advisable under applicable laws or regulations.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conversion or Exchange Rights</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will set forth in the applicable prospectus supplement the terms under which a series of debt securities may be convertible into or exchangeable for our common stock, our preferred stock or other securities (including securities of a third party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third party) that the holders of the series of debt securities receive would be subject to adjustment.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidation, Merger or Sale</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate. If the debt securities are convertible into or exchangeable for our other securities or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities into securities that the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger or sale.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Events of Default under the Indenture</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indentures with respect to any series of debt securities that we may issue:</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment has not been extended;</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has not been extended;</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive notice from the trustee or we and the trustee receive notice from the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if specified events of bankruptcy, insolvency or reorganization occur.</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will describe in each applicable prospectus supplement any additional events of default relating to the relevant series of debt securities.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default arises due to the occurrence of certain specified bankruptcy, insolvency or reorganization events, the unpaid principal, premium, if any, and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that:</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the direction so given by the holder is not in conflict with any law or the applicable indenture; and</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The indentures will provide that if an event of default has occurred and is continuing, the trustee will be required in the exercise of its powers to use the degree of care that a prudent person would use in the conduct of its own affairs. The trustee, however, may refuse to follow any direction that conflicts with law or the indenture, or that the trustee determines is unduly prejudicial to the rights of any other holder of the relevant series of debt securities, or that would involve the trustee in personal</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">liability. Prior to taking any action under the indentures, the trustee will be entitled to indemnification against all costs, expenses and liabilities that would be incurred by taking or not taking such action.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A holder of the debt securities of any series will have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies only if:</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the holder has given written notice to the trustee of a continuing event of default with respect to that series;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made a written request and such holders have offered reasonable indemnity to the trustee or security satisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting the proceeding as trustee; and</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities, or other defaults that may be specified in the applicable prospectus supplement.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indentures.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The indentures will provide that if a default occurs and is continuing and is actually known to a responsible officer of the trustee, the trustee must mail to each holder notice of the default within the earlier of 90 days after it occurs and 30 days after it is known by a responsible officer of the trustee or written notice of it is received by the trustee, unless such default has been cured or waived. Except in the case of a default in the payment of principal or premium of, or interest on, any debt security or certain other defaults specified in an indenture, the trustee shall be protected in withholding such notice if and so long as the Board of Directors, the executive committee or a trust committee of directors, or responsible officers of the trustee, in good faith determine that withholding notice is in the best interests of holders of the relevant series of debt securities.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Modification of Indenture; Waiver</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the terms of the indenture for any series of debt securities that we may issue, we and the trustee may change an indenture without the consent of any holders with respect to the following specific matters:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to fix any ambiguity, defect or inconsistency in the indenture;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to comply with the provisions described above under &#x201c;Description of Debt Securities &#x2014; Consolidation, Merger or Sale;&#x201d;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to add to, delete from or revise the conditions, limitations and restrictions on the authorized amount, terms or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to provide for the issuance of, and establish the form and terms and conditions of, the debt securities of any series as provided under &#x201c;Description of Debt Securities &#x2014; General,&#x201d; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to evidence and provide for the acceptance of appointment hereunder by a successor trustee;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to provide for uncertificated debt securities and to make all appropriate changes for such purpose;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to add such new covenants, restrictions, conditions or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred to us in the indenture; or</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to change anything that does not adversely affect the interests of any holder of debt securities of any series in any material respect.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any series of debt securities that we may issue or otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may only make the following changes with the consent of each holder of any outstanding debt securities affected:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extending the stated maturity of the series of debt securities;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption or repurchase of any debt securities; or</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:0.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discharge</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each indenture provides that, subject to the terms of the indenture and any limitation otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we may elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">register the transfer or exchange of debt securities of the series;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">replace stolen, lost or mutilated debt securities of the series;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain paying agencies;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hold monies for payment in trust;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recover excess money held by the trustee;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compensate and indemnify the trustee; and</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appoint any successor trustee.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to exercise our rights to be discharged, we will deposit with the trustee money or government obligations sufficient to pay all the principal of, and any premium and interest on, the debt securities of the series on the dates payments are due.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Form, Exchange and Transfer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indentures will provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depositary named by us and identified in a prospectus supplement with respect to that series. See &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Ownership of Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; below for a further description of the terms relating to any book-entry securities.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the option of the holder, subject to the terms of the indentures and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the terms of the indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we elect to redeem the debt securities of any series, we will not be required to:</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information Concerning the Trustee</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture and is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. However, upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment and Paying Agents</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest payment.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ranking Debt Securities</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to certain other indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount of subordinated debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The senior debt securities will be unsecured and will rank equally in right of payment to all our other senior unsecured debt. The senior indenture does not limit the amount of senior debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section11"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF WARRANTS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently or together with common stock, preferred stock or debt securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may issue the warrants under a warrant agreement that we will enter into with a warrant agent to be selected by us. If selected, the warrant agent will act solely as an agent of ours in connection with the warrants and will not act as an agent for the holders or beneficial owners of the warrants. If applicable, we will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a Current Report on Form 8-K that we file with the SEC, the form of warrant agreement, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering before the issuance of the related series of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. We urge you to read the applicable prospectus supplement and any applicable free writing prospectus related to the particular series of warrants that we sell under this prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will describe in the applicable prospectus supplement the terms relating to a series of warrants, including:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the offering price and aggregate number of warrants offered;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the currency for which the warrants may be purchased;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if applicable, the date on and after which the warrants and the related securities will be separately transferable;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of any rights to redeem or call the warrants;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the dates on which the right to exercise the warrants will commence and expire;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the manner in which the warrant agreements and warrants may be modified;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United States federal income tax consequences of holding or exercising the warrants;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of the securities issuable upon exercise of the warrants; and</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise of Warrants</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to us or the warrant agent as applicable.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enforceability of Rights by Holders of Warrants</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If selected, each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section12"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF UNITS</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the units that we may offer under this prospectus.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the terms we have summarized below will apply generally to any units that we may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a Current Report on Form 8-K that we file with the SEC, the form of unit agreement that describes the terms of the series of units</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries of material terms and provisions of the units are subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the particular series of units that we sell under this prospectus, as well as the complete unit agreement and any supplemental agreements that contain the terms of the units.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may issue units comprised of one or more debt securities, shares of common stock, shares of preferred stock and warrants in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will describe in the applicable prospectus supplement the terms of the series of units, including:</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any provisions of the governing unit agreement that differ from those described below; and</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions described in this section, as well as those described under &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Capital Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Debt Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Warrants</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; will apply to each unit and to any common stock, preferred stock, debt security or warrant included in each unit, respectively.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unit Agent</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The name and address of the unit agent, if any, for any units we offer will be set forth in the applicable prospectus supplement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuance in Series</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may issue units in such amounts and in numerous distinct series as we determine.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enforceability of Rights by Holders of Units</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in the unit.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, the unit agents and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that certificate for any purpose and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary. See &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Ownership of Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section13">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEGAL OWNERSHIP OF SECURITIES</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary or warrant agent maintain for this purpose as the &#x201c;holders&#x201d; of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#x201c;indirect holders&#x201d; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Book-Entry Holders</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#x2019;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#x2019;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Street Name Holders</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may terminate a global security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#x201c;street name.&#x201d; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not legal holders, of those securities.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal Holders</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Considerations for Indirect Holders</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out:</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">how it handles securities payments and notices;</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether it imposes fees or charges;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">how it would handle a request for the holders&#x2019; consent, if ever required;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and how you can instruct it to send you securities registered in your own name so you can be a legal holder, if that is permitted in the future;</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and</font></div></div><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.5671520255429483%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the securities are in book-entry form, how the depositary&#x2019;s rules and procedures will affect these matters.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Global Securities</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, NY, known as DTC, will be the depositary for all securities issued in book-entry form.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;&#x2014; Special Situations When A Global Security Will Be Terminated</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Considerations For Global Securities</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an indirect holder, an investor&#x2019;s rights relating to a global security will be governed by the account rules of the investor&#x2019;s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are issued only as global securities, an investor should be aware of the following:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the depositary&#x2019;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#x2019;s interest in the global security. We and any applicable trustee have no responsibility for any aspect of the depositary&#x2019;s actions or for its records of ownership interests in the global security. We and the trustee also do not supervise the depositary in any way;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial institutions that participate in the depositary&#x2019;s book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Situations When A Global Security Will Be Terminated</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A global security will terminate when the following special situations occur:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if we notify any applicable trustee that we wish to terminate that global security; or</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we, nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section14"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PLAN OF DISTRIBUTION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may sell the securities being offered hereby in one or more of the following ways from time to time:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">through agents to the public or to investors;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to underwriters for resale to the public or to investors;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negotiated transactions;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">block trades;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">directly to investors; or</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">through a combination of any of these methods of sale.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As set forth in more detail below, the securities may be distributed from time to time in one or more transactions:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at a fixed price or prices, which may be changed;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at market prices prevailing at the time of sale;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at prices related to such prevailing market prices; or</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at negotiated prices.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will set forth in a prospectus supplement the terms of that particular offering of securities, including:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the name or names of any agents or underwriters;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the purchase price of the securities being offered and the proceeds we will receive from the sale;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any over-allotment options under which underwriters may purchase additional securities from us;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any agency fees or underwriting discounts and other items constituting agents&#x2019; or underwriters&#x2019; compensation;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any initial public offering price;</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any discounts or concessions allowed or re-allowed or paid to dealers; and</font></div></div><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any securities exchanges or markets on which such securities may be listed.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Only underwriters named in an applicable prospectus supplement are underwriters of the securities offered by that prospectus supplement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If underwriters are used in an offering, we will execute an underwriting agreement with such underwriters and will specify the name of each underwriter and the terms of the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters and any dealers) in a prospectus supplement. The securities may be offered to the public either through underwriting syndicates represented by managing underwriters or directly by one or more investment banking firms or others, as designated. If an underwriting syndicate is used, the managing underwriter(s) will be specified on the cover of the prospectus supplement. If underwriters are used in the sale, the offered securities will be acquired by the underwriters</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for their own accounts and may be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. Unless otherwise</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">set forth in the prospectus supplement, the obligations of the underwriters to purchase the offered securities will be subject to conditions precedent and the underwriters will be obligated to purchase all of the offered securities if any are purchased.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may grant to the underwriters options to purchase additional securities to cover over-allotments, if any, at the public offering price, with additional underwriting commissions or discounts, as may be set forth in a related prospectus supplement. The terms of any over-allotment option will be set forth in the prospectus supplement for those securities.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we use a dealer in the sale of the securities being offered pursuant to this prospectus or any prospectus supplement, we will sell the securities to the dealer, as principal.  The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale.  The names of the dealers and the terms of the transaction will be specified in a prospectus supplement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may sell the securities directly or through agents we designate from time to time.  We will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, any agent will act on a best-efforts basis for the period of its appointment.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may authorize agents or underwriters to solicit offers by institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the sale of the securities, underwriters, dealers or agents may receive compensation from us or from purchasers of the common stock for whom they act as agents in the form of discounts, concessions or commissions. Underwriters may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of the securities, and any institutional investors or others that purchase common stock directly and then resell the securities, may be deemed to be underwriters, and any discounts or commissions received by them from us and any profit on the resale of the common stock by them may be deemed to be underwriting discounts and commissions under the Securities Act.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may provide agents and underwriters with indemnification against particular civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to such liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act.  In addition, we may enter into derivative transactions with third parties (including the writing of options), or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with such a transaction, the third parties may, pursuant to this prospectus and the applicable prospectus supplement, sell securities covered by this prospectus and the applicable prospectus supplement. If so, the third party may use securities borrowed from us or others to settle such sales and may use securities received from us to close out any related short positions. We may also loan or pledge securities covered by this prospectus and the applicable prospectus supplement to third parties, who may sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and the applicable prospectus supplement. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement or in a post-effective amendment.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To facilitate an offering of a series of securities, persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect the market price of the securities. This may include over-allotments or short sales of the securities, which involves the sale by persons participating in the offering of more securities than have been sold to them by us.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In those circumstances, such persons would cover such over-allotments or short positions by purchasing in the open market or by exercising the over-allotment option granted to those persons. In addition, those persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to underwriters or dealers participating in any such offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. Such transactions, if commenced, may be discontinued at any time. We make no representation or prediction as to the direction or magnitude of any effect that the transactions described above, if implemented, may have on the price of our securities.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise specified in the applicable prospectus supplement, each class or series of securities will be a new issue with no established trading market, other than our common stock, which is listed on The Nasdaq Capital Market. We may elect to list any other class or series of securities on any exchange or market, but we are not obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the securities.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to comply with the securities laws of some U.S. states or territories, if applicable, the securities offered pursuant to this prospectus will be sold in those states only through registered or licensed brokers or dealers. In addition, in some states securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and complied with.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of these activities at any time.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any underwriters who are qualified market makers on The Nasdaq Capital Market may engage in passive market making transactions in the securities on The Nasdaq Capital Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security. If all independent bids are lowered below the passive market maker&#x2019;s bid, however, the passive market maker&#x2019;s bid must then be lowered when certain purchase limits are exceeded.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="legalmatters1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEGAL MATTERS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The validity of the issuance of the securities offered hereby will be passed upon for us by Sheppard, Mullin, Richter &amp; Hampton LLP, New York, NY.  Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section16"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXPERTS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements of Cardiff Oncology, Inc. as of December 31, 2024 and 2023 and for the years then ended incorporated by reference in this prospectus and in the registration statement have been so incorporated in reliance on the report of BDO USA, P.C., an independent registered public accounting firm given on the authority of said firm as experts in auditing and accounting.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section17"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHERE YOU CAN FIND MORE INFORMATION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus constitutes a part of the registration statement on Form S-3 that we have filed with the SEC under the Securities Act. As permitted by the SEC&#x2019;s rules, this prospectus supplement and any accompanying prospectus, which forms a part of the registration statement, do not contain all of the information that is included in the registration statement. You will find additional information about us in the registration statement. Any statement made in this prospectus supplement or any accompanying prospectus concerning legal documents are not necessarily complete and you should read the documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document or matter.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the reporting requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC&#x2019;s website at</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> http://www.sec.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We also maintain a website at</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> www.cardiffoncology.com</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing or telephoning us at: 11055 Flintkote Avenue, San Diego, California, 92121, (858) 952-7570.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section18"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INCORPORATION OF DOCUMENTS BY REFERENCE</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus supplement is part of the registration statement, but the registration statement includes and incorporates by reference additional information and exhibits. The SEC permits us to &#x201c;incorporate by reference&#x201d; the information contained in documents we file with the SEC, which means that we can disclose important information to you by referring you to those documents rather than by including them in this prospectus supplement. Information that is incorporated by reference is considered to be part of this prospectus supplement and you should read it with the same care that you read this prospectus supplement and the accompanying prospectus. Information that we file later with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus supplement, and will be considered to be a part of this prospectus supplement from the date those documents are filed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We incorporate by reference the documents listed below, all filings filed by us pursuant to the Exchange Act after the date of the registration statement of which this prospectus supplement and the accompanying prospectus forms a part, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the time that all securities covered by this prospectus supplement have been sold; provided, however, that we are not incorporating any information furnished under either Item 2.02 or Item 7.01 of any current report on Form 8-K:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000095017025028992/crdf-20241231.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 27, 2025</font></a><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p> <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our Quarterly Report on Form 10-Q for the three months ended March 31, 2025 filed with the SEC on </font><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000095017025066886/crdf-20250331.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 8, 2025</font></a><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our Current Report on Form 8-K filed with the SEC on </font><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000095017025002076/crdf-20250103.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 6, 2025</font></a><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000095017025060074/crdf-20250429.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our definitive proxy statement filed with the SEC on April 29, 2025</font></a><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; and</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000110465912039425/a12-9768_98a12b.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on May 23, 2012, including any amendments or reports filed with the SEC for the purposes of updating such description</font></a><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any statements made in a document incorporated by reference in this prospectus supplement are deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement in this prospectus supplement or in any other subsequently filed document, which is also incorporated by reference, modifies or supersedes the statement. Any statement made in this prospectus supplement is deemed to be modified or superseded to the extent a statement in any subsequently filed document, which is incorporated by reference in this prospectus supplement, modifies or supersedes such statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information relating to us contained in this prospectus supplement should be read together with the information in the documents incorporated by reference. In addition, certain information, including financial information, contained in this prospectus or incorporated by reference in this prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">should be read in conjunction with documents we have filed with the SEC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will provide to each person, including any beneficial holder, to whom a prospectus is delivered, at no cost, upon written or oral request, a copy of any or all of the information that has been incorporated by reference in the prospectus but not delivered with the prospectus. Requests for documents should be by writing to or telephoning us at the following address: Cardiff Oncology, Inc., 11055 Flintkote Avenue, San Diego, CA 92121; (858) 952-7570. Exhibits to these filings will not be sent unless those exhibits have been specifically incorporated by reference in such filings.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ff4040;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in this prospectus is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ff4040;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRELIMINARY PROSPECTUS</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ff4040;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to completion, dated May 8, 2025</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                                                                       </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83777979_2.jpg" alt="img83777979_2.jpg" style="width:200px;height:53px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Up to $150,000,000</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into an Open Market Sale Agreement</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or the Sales Agreement, with Jefferies LLC, or Jefferies, dated March 12, 2021, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $150 million from time to time through Jefferies, acting as sales agent.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock trades on The Nasdaq Capital Market under the symbol &#x201c;CRDF.&#x201d; On May 5, 2025, the last reported sale price of our common stock on the Nasdaq Capital Market was $2.68 per share.</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of our common stock, if any, under this prospectus may be made in sales deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Jefferies is not required to sell any specific number or dollar amount of securities, but will act as sales agent on a best efforts basis and use commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between us and Jefferies. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jefferies will be entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per common share sold under the Sales Agreement. In connection with the sale of our common stock on our behalf, Jefferies will be deemed to be an &#x201c;underwriter&#x201d; within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Jefferies with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended or the Exchange Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investing in our common stock involves a high degree of risk. See &#x201c;Risk Factors&#x201d; beginning on page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this prospectus and in the documents incorporated by reference into this prospectus.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus or the accompanying prospectus. Any representation to the contrary is a criminal offense.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jefferies</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The date of this prospectus is                 , 2025.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.59in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section20">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PROSPECTUS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:85.24%;box-sizing:content-box;"></td>
     <td style="width:14.76%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">About This Prospectus</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disclosure Regarding Forward-Looking Statements</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prospectus Summary</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Offering</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">9</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk Factors</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Use of Proceeds</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">14</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilution</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">14</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Plan of Distribution</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">16</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal Matters</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">17</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Experts</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">17</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Where You Can Find More Information</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">17</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incorporation of Documents by Reference</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">18</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are responsible for the information contained and incorporated by reference in this prospectus, in any accompanying prospectus supplement, and in any related free writing prospectus we prepare or authorize. We have not and Jefferies has not authorized anyone to give you any other information, and neither we nor Jefferies take any responsibility for any other information that others may give you. If you are in a jurisdiction where offers to sell, or solicitations of offers to purchase, the securities offered by this documentation are unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this document does not extend to you. The information contained in this document speaks only as of the date of this document, unless the information specifically indicates that another date applies. Our business, financial condition, results of operations and prospects may have changed since those dates.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section21"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ABOUT THIS PROSPECTUS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus relates to the offering of our common stock. Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus, together with the accompanying prospectus and the information incorporated by reference as described under the heading &#x201c;Where You Can Find More Information&#x201d; and &#x201c;Incorporation of Documents by Reference.&#x201d; This prospectus is deemed a prospectus to the accompanying prospectus contained in the registration statement of which this prospectus forms a part. These documents contain important information that you should consider when making your investment decision.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus describes the specific terms of the common stock we are offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the accompanying prospectus and the information contained in any document incorporated by reference in this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#x2014;for example, a document incorporated by reference into this prospectus&#x2014;the statement in the document having the later date modifies or supersedes the earlier statement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should rely only on the information contained or incorporated by reference in this prospectus and the accompanying prospectus or contained in any free writing prospectus prepared by or on our behalf. We have not, and the underwriters have not, authorized anyone to provide you with different information. The distribution of this prospectus and sale of these securities in certain jurisdictions may be restricted by law. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus, the accompanying prospectus and the documents incorporated by reference in this prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trademarks, service marks or trade names of any other companies appearing in this prospectus  are the property of their respective owners. Use or display by us of trademarks, service marks or trade names owned by others is not intended to and does not imply a relationship between us and, or endorsement or sponsorship by, the owners of the trademarks, service marks or trade names.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section22"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus, the accompanying prospectus and the documents incorporated by reference herein and therein contain, in addition to historical information, certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation and availability of resources. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, you can identify forward-looking statements by terminology, such as &#x201c;expects,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;intends,&#x201d; &#x201c;estimates,&#x201d; &#x201c;plans,&#x201d; &#x201c;believes,&#x201d; &#x201c;seeks,&#x201d; &#x201c;may,&#x201d; &#x201c;should&#x201d;, &#x201c;could&#x201d; or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus or incorporated herein by reference.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from those expressed or implied in our written or oral forward-looking statements may be found in this prospectus under the heading &#x201c;Risk Factors&#x201d; and in our Annual Report on Form 10-K for the year ended December 31, 2024 under the headings &#x201c;Risk Factors&#x201d; and &#x201c;Business,&#x201d; as updated in our Quarterly Report(s) on Form 10-Q.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-looking statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this prospectus and incorporated herein by reference, and particularly our forward-looking statements, by these cautionary statements.</font></p><p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div class="page-border" style="margin-left:0.0pt;margin-right:0.0pt;border-top:1pt solid #000000;border-right:1pt solid #000000;border-left:1pt solid #000000;border-bottom:1pt solid #000000;"><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="prospectussummary"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PROSPECTUS SUMMARY</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following summary highlights certain of the information contained elsewhere in or incorporated by reference into this prospectus. Because this is only a summary, however, it does not contain all the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in or incorporated by reference into this prospectus. Before you make an investment decision, you should read this entire prospectus and the accompanying prospectus carefully, including the risks of investing in our securities discussed under the section of this prospectus entitled &#x201c;Risk Factors&#x201d; and similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unless the context otherwise requires, references to &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us,&#x201d; &#x201c;Cardiff&#x201d; or the &#x201c;Company&#x201d; in this prospectus mean Cardiff Oncology, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.413%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care (&#34;SoC&#34;) therapeutics. We are focusing our clinical program in indications such as RAS-mutated metastatic colorectal cancer (&#34;mCRC&#34;), as well as in investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma (&#34;mPDAC&#34;), small cell lung cancer (&#34;SCLC&#34;), and triple negative breast cancer (&#34;TNBC&#34;). Our clinical development programs incorporate tumor genomics and biomarker assays to refine assessment of patient response to treatment.</font></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Lead Drug Candidate, Onvansertib</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Onvansertib is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe the attributes of onvansertib described below, as well as early clinical evidence of favorable safety and efficacy, with expected on-target, manageable and tolerable side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Onvansertib is highly potent and highly selective against the PLK1 enzyme (IC</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> = 2nM; IC</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is the concentration for 50% inhibition), compared to prior PLK1 inhibitors that were pan-inhibitors of several PLK targets.  Low or no activity of onvansertib was observed on a panel of 63 kinases (IC50&gt;500 nM), including the PLK members PLK2 and PLK3 (IC</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&gt;10,000 nM);</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Onvansertib is orally bioavailable, allowing for relative ease and flexibility of dosing;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Onvansertib has a relatively short drug half-life of 24 hours, allowing for flexible dosing and scheduling that has demonstrated a favorable safety profile across multiple clinical trials.</font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In vitro</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> studies have shown synergistic effects when onvansertib was administered in combination with different cytotoxic agents including microtubule-targeting agents, topoisomerase 1 inhibitors, antimetabolites, alkylating agents, proteasome inhibitors, kinase inhibitors, PARP inhibitors, BCL-2 inhibitors, and androgen biosynthesis inhibitors.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> combination studies have confirmed the positive results obtained </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and additive or synergistic effects on efficacy have been observed in xenograft models of onvansertib in combination with irinotecan, 5-fluorouracil (&#34;5-FU&#34;), abiraterone, PARP inhibitors, venetoclax, paclitaxel, or bevacizumab. Combining onvansertib with SoC cancer agents may provide opportunities for synergy with many cancer therapies.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are several ongoing and planned clinical trials of onvansertib in multiple indications: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RAS-mutated mCRC Program:</font></p></div></div><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div class="page-border" style="margin-left:0.0pt;margin-right:0.0pt;border-top:1pt solid #000000;border-right:1pt solid #000000;border-left:1pt solid #000000;border-bottom:1pt solid #000000;"><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRDF-004 Randomized Clinical Trial in First-Line RAS-mutated mCRC</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRDF-004 is a Phase 2 open-label, randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC. The primary objectives of the CRDF-004 trial are to evaluate onvansertib&#x2019;s safety and efficacy in combination with the SoC, as well as to evaluate two doses of onvansertib, 20mg and 30mg, given in combination with SoC, against SoC alone. The primary endpoint of the trial is objective response rate (&#34;ORR&#34;). Progression-free survival and duration of response will be secondary endpoints.  This trial is conducted in partnership with Pfizer Ignite, an end-to-end service for biotech companies, and it is expected to enroll approximately 90 evaluable patients. For more information, please visit NCT06106308 at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicialtrials.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingent upon the results of CRDF-004, we plan to initiate CRDF-005, a Phase 3, randomized trial with registrational intent. The FDA has agreed that a seamless trial with an interim endpoint of ORR, with duration of response, is acceptable to pursue accelerated approval, with progression-free survival and trend in overall survival being the endpoints for full approval.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data presented on December 10, 2024 provided initial results from the ongoing CRDF-004 Phase 2 randomized clinical trial in first-line RAS-mutated metastatic colorectal cancer. ORR, as of the data cut-off date of November 26, 2024, are shown below.</font></p>
     <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
      <tr style="visibility:collapse;">
       <td style="width:24.07%;box-sizing:content-box;"></td>
       <td style="width:1.24%;box-sizing:content-box;"></td>
       <td style="width:24.07%;box-sizing:content-box;"></td>
       <td style="width:1.24%;box-sizing:content-box;"></td>
       <td style="width:24.07%;box-sizing:content-box;"></td>
       <td style="width:1.24%;box-sizing:content-box;"></td>
       <td style="width:24.07%;box-sizing:content-box;"></td>
      </tr>
      <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Control Arm (SoC alone)</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">20mg dose of onvansertib + SoC</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">30mg dose of onvansertib + SoC</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All onvansertib patients</font></p></td>
      </tr>
      <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33% ORR<br>(3 of 9)</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50% ORR<br>(5 of 10)</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64% ORR<br>(7 of 11)</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57% ORR<br>(12 of 21)</font></p></td>
      </tr>
     </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Spider Plots, displaying the change in tumor size from baseline for each patient over time, demonstrate deeper responses observed in patients receiving the 30mg dose of onvansertib in combination with the SoC compared to both the control arms and 20mg dose of onvansertib arms.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img83777979_1.jpg" alt="img83777979_1.jpg" style="width:602px;height:326px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note: Radiographic response determined per RECIST 1.1 by blinded independent central review. Spider plot reflects interim data as of November 26, 2024 from an ongoing trial and unlocked database.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Onvansertib in combination with chemo/bevacizumab was well-tolerated and there have been no major or unexpected toxicities observed.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1b/2 Clinical Trial in Second-Line KRAS-mutated mCRC</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC, completed enrollment in October 2022.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary objectives of this trial were to evaluate the Dose-Limiting Toxicities (&#34;DLTs&#34;), maximum tolerated dose (&#34;MTD&#34;) and recommended Phase 2 dose (&#34;RP2D&#34;) of onvansertib in combination with FOLFIRI and bevacizumab (Phase 1b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div class="page-border" style="margin-left:0.0pt;margin-right:0.0pt;border-top:1pt solid #000000;border-right:1pt solid #000000;border-left:1pt solid #000000;border-bottom:1pt solid #000000;"><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and to continue to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab patients with KRAS-mutated mCRC (Phase 2). For more information, please visit NCT03829410 at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicialtrials.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data presented on August 7, 2023, provided an update of the ongoing TROV-054 Phase 1b/2 single arm clinical trial in KRAS-mutated metastatic colorectal cancer:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ORR across all evaluable patients was 29%, with 19 of 66 evaluable patients achieving an objective response. Responses have been observed across multiple KRAS variants;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Median duration of response (&#34;mDoR&#34;) across all evaluable patients was 12.0 months (95% confidence interval (&#34;CI&#34;): 8.9 &#x2013; not reached);</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Median progression free survival (&#34;mPFS&#34;) across all evaluable patients was 9.3 months (95% CI: 7.8 &#x2013; 14). Historical control trials of different drug combinations, including the SoC of FOLFIRI with bevacizumab, in similar patient populations have shown ORR and mPFS of 5 &#x2013; 13% and ~4.5 &#x2013; 6.7 months, respectively;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A subgroup analysis of patients who were bevacizumab na&iuml;ve when they entered second-line therapy vs. patients who had received prior bevacizumab in first-line therapy showed that patients who were bevacizumab na&iuml;ve (n=15) had an ORR of 73% and mPFS of 15 months, which is well above historical controls. In contrast, patients previously treated with bevacizumab (n=51) had an ORR of 16% and mPFS of 7.8 months;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data on Treatment Emergent Adverse Events (&#34;TEAEs&#34;) on the trial showed that onvansertib is well-tolerated when used in combination with FOLFIRI and bevacizumab.  The more severe, grade 4 TEAEs are either neutropenia or leukopenia, which are common events in patients treated with FOLFIRI and bevacizumab. None of the patients with grade 4 TEAEs discontinued treatment due to their condition and all resolved without issue. There were no major or unexpected toxicities seen in the trial;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data from the Phase 1b portion of this trial was published in the peer-reviewed journal Clinical Cancer Research, February 6, 2024 edition; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data from the Phase 2 portion of this trial was published online in the peer-reviewed journal of Clinical Oncology on October 30, 2024. </font></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the interim results of the TROV-054 trial, we designed the ONSEMBLE trial (CRDF-003) as the next phase of our mCRC program.  Upon further review of the clinical data from the bevacizumab na&iuml;ve subgroup (those patients who did not receive bevacizumab in their first-line therapy), the preclinical data on the mechanism of action and the feedback from the FDA on our clinical development strategy, we made the decision to discontinue enrollment in the ONSEMBLE trial and to initiate the CRDF-004 clinical trial.</font></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2 Clinical Trial in Second-Line RAS-mutated mCRC</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ONSEMBLE trial (CRDF-003) was a Phase 2 randomized, open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with RAS-mutated mCRC. The ONSEMBLE trial completed enrollment in August 2023 as part of our shift to a first-line mCRC program. The primary objectives of the ONSEMBLE trial were to evaluate onvansertib&#x2019;s safety and efficacy in combination with FOLFIRI and bevacizumab, as well as to evaluate two doses of onvansertib, 20mg and 30mg, given in combination with FOLFIRI and bevacizumab, against FOLFIRI and bevacizumab alone. The primary endpoint of the trial was ORR. For more information, please visit NCT05593328 at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicialtrials.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ORR data from the randomized ONSEMBLE trial validates the findings observed in our earlier single-arm Phase 1b/2 KRAS-mutated mCRC trial (TROV-054). In the ONSEMBLE trial, objective responses were observed only in bevacizumab na&iuml;ve patients, not bevacizumab exposed patients. In addition, these objective responses were present only in bevacizumab na&iuml;ve patients randomized to the experimental arms of onvansertib in combination with FOLFIRI and bevacizumab versus bevacizumab na&iuml;ve patients randomized to the FOLFIRI and bevacizumab alone control arm.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mPDAC Program:</font></p><p style="margin-left:4.533%;text-indent:2.235%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1b/2 Investigator-Initiated Clinical Trial in First-Line mPDAC</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the FDA approved NALIRIFOX as a first-line treatment option for mPDAC. As a result, we are currently supporting a new investigator-initiated mPDAC Phase 1b/2 trial of onvansertib in combination with first-line SoC NALIRIFOX, which is now open for enrollment at the University of Kansas Medical Center. The trial replaced a previously</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div class="page-border" style="margin-left:0.0pt;margin-right:0.0pt;border-top:1pt solid #000000;border-right:1pt solid #000000;border-left:1pt solid #000000;border-bottom:1pt solid #000000;"><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">planned two-cohort, non-randomized Phase 2 trial of onvansertib in combination with first-line SoC Gemzar</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Abraxane</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> .  For more information, please visit NCT06736717 at</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> www.clinicaltrials.gov.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary objective in this study is to determine anti-tumor activity by measuring Overall Response Rate (ORR). The secondary objectives are to determine treatment safety based on toxicities in participants who have received at least one dose of onvansertib, to determine anti-tumor activity by Progression Free Survival (PFS), to determine anti-tumor activity by Disease Control Rate (DCR), to determine Overall Survival (OS).</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2 Clinical Trial in mPDAC</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan (Onivyde</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), leucovorin, and fluorouracil for 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> line treatment of patients with mPDAC, completed enrollment in October 2023.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The objective of this trial was to assess the safety and preliminary efficacy of onvansertib in combination with nanoliposomal irinotecan (Onyvide</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), 5-FU and leucovorin as a 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> line treatment in patients with mPDAC who have failed first-line gemcitabine-based therapy. For more information, please visit NCT04752696 at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicialtrials.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preliminary data presented on September 26, 2023, and updated on February 29, 2024, showed promising data that caused us to shift the program to a first-line investigator initiated trial.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mPDAC biomarker discovery trial</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The investigator-initiated biomarker discovery trial is exploring the impact of onvansertib 10-day monotherapy on tumors in mPDAC patients, and enrolled at the Oregon Health &amp; Science University (OHSU) Knight Cancer Institute. Enrollment for this trial is closed.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preliminary data were presented on September 26, 2023. One patient demonstrated an 86% decrease in Ki67, a well-established biomarker of tumor proliferation, and a 28% decrease in CA 19-9, a clinically-used biomarker to monitor treatment response.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Clinical Programs:</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2 Investigator-Initiated Clinical Trial in SCLC</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A single-arm, two-stage, Phase 2 trial of onvansertib monotherapy in patients with relapsed SCLC is open for enrollment at the University of Maryland, Baltimore. The trial is designed to enroll 15 patients in Stage 1, with the study proceeding to Stage 2 if 2 or more Stage 1 patients achieve an objective response. Stage 2 is designed to enroll an additional 20 patients. The primary endpoint of the trial is ORR, while key secondary endpoints include PFS and overall survival. For more information, please visit NCT05450965 at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicialtrials.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An examination of the safety data from the first six patients by the institutional review board confirmed the trial can continue to enroll as planned. Preliminary efficacy data for seven patients presented on September 26, 2023, showed one confirmed partial response (&#x201c;PR&#x201d;), three stable disease (&#x201c;SD&#x201d;) and three progressive disease (&#x201c;PD&#x201d;). The disease control rate (&#x201c;DCR&#x201d;), including PR and SD, is 57% (4 of 7 patients).</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1b Investigator-Initiated Clinical Trial in TNBC</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A single-arm, Phase 1b trial of onvansertib in combination with paclitaxel in patients with unresectable locally advanced or metastatic TNBC is open for enrollment at Dana Farber Cancer Institute (&#34;DFCI&#34;). In Phase 1b, approximately 14-16 patients will be treated with different doses of onvansertib in combination with a fixed dose of paclitaxel to determine the maximum tolerated dose and the safety and efficacy of onvansertib in combination with paclitaxel. For more information, please visit NCT05383196 at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicialtrials.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Associated with Our Business</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to raise substantial additional capital to develop and commercialize, our product candidate, onvansertib, and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.</font></div></div></div></div><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div class="page-border" style="margin-left:0.0pt;margin-right:0.0pt;border-top:1pt solid #000000;border-right:1pt solid #000000;border-left:1pt solid #000000;border-bottom:1pt solid #000000;"><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidate is in the early stages of clinical development and its commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our product candidate, our business will be materially harmed.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the results of preclinical studies or clinical trials for our product candidate, including those that are subject to existing or future license or collaboration agreements, are unfavorable or delayed, we could be delayed or precluded from the further development or commercialization of our product candidate, which could materially harm our business.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If third party vendors upon whom we intend to rely on to conduct our preclinical studies or clinical trials do not perform or fail to comply with strict regulations, these studies or trials of our product candidate may be delayed, terminated, or fail, or we could incur significant additional expenses, which could materially harm our business.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, and our collaborators, must comply with extensive government regulations in order to advance our product candidate through the development process and ultimately obtain and maintain marketing approval for our products in the U.S. and abroad.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience in the development of therapeutic product candidates and therefore may encounter difficulties developing our product candidate or managing our operations in the future.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays in clinical testing could result in increased costs to us and delay our ability to generate revenue.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidate, our business will be substantially harmed.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security threats to our information technology infrastructure and/or our physical buildings could expose us to liability and damage our reputation and business.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the manufacturers upon whom we rely fail to produce our product candidate, in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of our product candidate.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidate, if approved for sale, may not gain acceptance among physicians, patients and the medical community, thereby limiting our potential to generate revenues.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we materially breach or default under the Nerviano Licensing Agreement, Nerviano will have the right to terminate the agreement and we could lose critical license rights, which would materially harm our business.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Information</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were originally incorporated under the laws of the State of Florida in April 2002. In January 2010, we re-incorporated under the laws of the State of Delaware and changed our name to Trovagene, Inc. In May 2012, our common stock was listed on The Nasdaq Capital Market (&#34;Nasdaq&#34;) under the ticker symbol TROV. In May 2020 we changed our name to Cardiff Oncology, Inc. and our Nasdaq ticker symbol changed to CRDF. Our corporate website address is </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.cardiffoncology.com</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div><div class="page-border-spacing" style="padding-left:3.0%;padding-right:3.0%;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="theoffering"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE OFFERING</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:37.68%;box-sizing:content-box;"></td>
     <td style="width:3.66%;box-sizing:content-box;"></td>
     <td style="width:58.66%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:28.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common stock offered by us:</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares of our common stock having an aggregate offering price of up to $150,000,000.</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:69.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common stock to be outstanding immediately after this offering:</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Up to 122,496,003 shares, assuming the sale of up to 55,970,149 shares hereunder at a price of $2.68 per share, the closing price per share on The Nasdaq Capital Market on May 5, 2025, for aggregate gross proceeds of $150,000,000. Actual shares issued will vary depending on the sales prices under this offering.</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:64.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Manner of offering:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x201c;At the market offering&#x201d; that may be made from time to time on The Nasdaq Capital Market or other existing trading market for our common stock through our sales agent, Jefferies LLC. See &#x201c;Plan of Distribution&#x201d; on page </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;of this prospectus.</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:104.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Use of Proceeds:</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Our management will retain broad discretion regarding the allocation and use of the net proceeds. We currently intend to use the net proceeds from this offering for general corporate purposes, including the development and commercialization of our products, research and development, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures. We may also use a portion of the remaining net proceeds, if any, to acquire or invest in complementary businesses, products and technologies, although we have no current commitments or agreements with respect to any acquisitions as of the date hereof. See &#x201c;Use of Proceeds&#x201d; on page </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:64.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Risk factors:</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investing in our common stock involves risks. See &#x201c;Risk Factors&#x201d; beginning on page </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;of this prospectus and in the documents incorporated by reference into this prospectus for a discussion of factors you should carefully consider before deciding to invest in our common stock.</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.85pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nasdaq Capital Market symbol:</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CRDF</font></p></td>
    </tr>
   </table> <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless we indicate otherwise, all information in this prospectus is based on 66,525,854 shares of common stock outstanding as of May 5, 2025 and excludes as of that date:</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&middot; 877 shares of common stock issuable upon conversion of outstanding Series A Convertible Preferred Stock;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p> <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&middot; 10,858,112 shares of our common stock issuable upon exercise of outstanding stock options under our stock incentive plans at a weighted average exercise price of $3.80 per share;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&middot; 2,787,714 shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $2.40 per share; and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&middot; 668,803 shares of common stock reserved for future grants and awards under our stock incentive plans.</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section25"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISK FACTORS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should consider carefully the risks described below and discussed under the section captioned &#x201c;Risk Factors&#x201d; in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, which are each incorporated by reference in this prospectus and the accompanying prospectus in their entirety, as well as any amendment or update to our risk factors reflected in subsequent filings with the SEC, together with other information in this prospectus, the accompanying prospectus, and the information and documents incorporated by reference that we have authorized for use in connection with this offering. If any of these risks actually occur, our business, financial condition, results of operations or cash flows could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. The risks and uncertainties summarized and described below are not intended to be exhaustive and are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business, prospects, financial condition and results of operations. Certain statements in this prospectus are forward-looking statements. Please also see the section entitled &#x201c;Disclosure Regarding Forward-Looking Statements.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to this Offering and Our Common Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock historically has been, and we expect will continue to be, subject to significant fluctuations over short periods of time. For example, during the year ended December 31, 2024, the closing price of our common stock ranged from a low of $1.46 to a high of $5.91. These fluctuations may be due to various factors, many of which are beyond our control, including:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">technological innovations or new products and services introduced by us or our competitors;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial results relating to our tests or those of our competitors;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements or press releases relating to the industry or to our own business or prospects;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coverage and reimbursement decisions by third party payors, such as Medicare and other managed care organizations;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulation and oversight of our product candidates and services, including by the FDA, Centers for Medicare &amp; Medicaid Services and comparable foreign agencies;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the establishment of partnerships with clinical reference laboratories;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">healthcare legislation;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">intellectual property disputes;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions or departures of key personnel;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our common stock;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to integrate operations, technology, products and services;</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to execute our business plan;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operating results below expectations;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of any strategic relationship;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">industry developments;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic and other external factors;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">catastrophic weather and/or global disease outbreaks, such as the recent COVID-19 pandemic; and</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">period-to-period fluctuations in our financial results.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, market fluctuations, as well as general political and economic conditions, could materially adversely affect the market price of our securities. Because we are a development stage company with no revenue from operations to date, other than licensing, milestone and royalty income, you should consider any one of these factors to be material. Our stock price may fluctuate widely as a result of any of the foregoing.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If you purchase our common stock in this offering, you may incur immediate and substantial dilution in the net tangible book value of your shares.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p> <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering. Assuming that an aggregate of 55,970,149 shares of our common stock are sold at a price of $2.68 per share, the last reported sale price of our common stock on The Nasdaq Capital Market on May 5, 2025, for aggregate gross proceeds of approximately $150,000,000, and after deducting commissions and estimated offering expenses payable by us, you would experience immediate dilution of $0.91 per share, representing the difference between our as adjusted net tangible book value per share as of March 31, 2025 after giving effect to this offering and the assumed public offering price. The exercise of outstanding stock options and warrants and conversion of preferred stock will result in further dilution of your investment.</font></p> <p style="text-indent:3.747%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This dilution would be due to the substantially lower price paid by some of our investors who purchased shares prior to this offering as compared to the assumed price offered to the public in this offering and the exercise of stock options granted to our employees, directors and consultants as well as the exercise of outstanding warrants and conversion of outstanding preferred stock. As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. Further, because we expect we will need to raise additional capital to fund our future activities, we may in the future sell substantial amounts of common stock or securities exercisable or convertible into or exchangeable for common stock.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we will have broad discretion and flexibility in how the net proceeds from this offering are used, we may use the net proceeds in ways in which you disagree.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to use the net proceeds from this offering for general corporate purposes, including the development and commercialization of our products, research and development, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures.  See &#x201c;Use of Proceeds&#x201d; on page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have not allocated specific amounts of the net proceeds from this offering for any of the foregoing purposes. Accordingly, our management will have significant discretion and flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the net proceeds are being used appropriately. It is possible that the net proceeds will be invested in a</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">way that does not yield a favorable, or any, return for us. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flow.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You may experience future dilution as a result of future equity offerings and other issuances of our securities. In addition, this offering and future equity offerings and other issuances of our common stock or other securities may adversely affect our common stock price.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities exercisable or convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may not be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or securities exercisable or convertible into common stock in future transactions may be higher or lower than the price per share in this offering. You will incur dilution upon exercise of any outstanding stock options or warrants, the conversion of any outstanding preferred stock or upon the issuance of shares of common stock under our stock incentive programs. In addition, the sale of shares in this offering and any future sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability of those shares of common stock for sale will have on the market price of our common stock.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have not paid dividends on our common stock in the past and do not expect to pay dividends on our common stock for the foreseeable future. Any return on investment may be limited to the value of our common stock.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never paid any cash dividends on our common stock. We expect that any income received from operations will be devoted to our future operations and growth. We do not expect to pay cash dividends on our common stock in the near future. Payment of dividends would depend upon our profitability at the time, cash available for those dividends, and other factors that our board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on an investor&#x2019;s investment will only occur if our stock price appreciates. In addition, the terms of the Series A Convertible Preferred Stock prohibit us from paying dividends to the holders of our common stock so long as any dividends due on the Series A Convertible Preferred Stock remain unpaid. Furthermore, the terms of any debt agreements may also preclude us from paying dividends. Investors in our common stock should not rely on an investment in our company if they require dividend income. We expect that only appreciation of the price of our common stock, if any, will provide a return to investors in this offering for the foreseeable future.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The common stock offered hereby will be sold in &#x201c;at the market&#x201d; offerings, and investors who buy shares at different times will likely pay different prices.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investors who purchase shares in this offering at different times will likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold, and there is no minimum or maximum sales price. Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices they paid.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The actual number of shares we will issue under the Sales Agreement, at any one time or in total, is uncertain.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver placement notices to Jefferies at any time throughout the term of the Sales Agreement. The number of shares that are sold by Jefferies after delivering a placement notice will fluctuate based on the market price of the common stock during the sales period and limits we set with Jefferies. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a smaller reporting company, and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently a &#x201c;smaller reporting company,&#x201d; as defined in Rule 405 under the Securities Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a smaller reporting company, we take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#x201c;smaller reporting companies,&#x201d; including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the provisions of Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, requiring that independent registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting. Decreased disclosures in our SEC filings due to our status as a &#x201c;smaller reporting company&#x201d; may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section26"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">USE OF PROCEEDS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $150 million from time to time. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under or fully utilize our Sales Agreement with Jefferies as a source of financing.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to use the net proceeds from the sale of the shares for general corporate purposes, including the development and commercialization of our products, research and development, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures. The expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures will depend on numerous factors, including the factors described under &#x201c;Risk Factors&#x201d; in this prospectus and in the documents incorporated by reference herein, as well as the amount of cash used in our operations.  We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. We may also use a portion of the remaining net proceeds, if any, to acquire or invest in complementary businesses, products and technologies, although we have no current commitments or agreements with respect to any acquisitions as of the date hereof. Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section27"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DILUTION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p> <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the public offering price per share and the as adjusted net tangible book value per share after this offering. As of March 31, 2025, our net tangible book value was $70.9 million, or $1.07 per share. Net tangible book value per share represents our total tangible assets (excluding deferred issuance costs) less our total liabilities, divided by the number of shares outstanding. Dilution with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After giving effect to the sale of 55,970,149 shares of common stock in this offering at an assumed public offering price of $2.68 per share, the last reported sale price of our common stock on The Nasdaq Capital Market on May 5, 2025, and after deducting commissions and estimated aggregate offering expenses payable by us, our as adjusted net tangible book value as of March 31, 2025 would have been approximately $216.3 million, or approximately $1.77 per share of common stock. This represents an immediate increase in as adjusted net tangible book value of $0.70 per share to our existing stockholders and an immediate dilution in net tangible book value of 0.91 per share to investors participating in this offering at the assumed public offering price.</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:70.76%;box-sizing:content-box;"></td>
     <td style="width:2.08%;box-sizing:content-box;"></td>
     <td style="width:12.54%;box-sizing:content-box;"></td>
     <td style="width:2.08%;box-sizing:content-box;"></td>
     <td style="width:12.54%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:15.85pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assumed public offering price per share</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	2.68</font></p></td>
    </tr>
    <tr style="height:15.85pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:6.75pt;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="margin-left:1.253%;text-indent:0;font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net tangible book value per share as of March 31, 2025</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	1.07</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:15.85pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:6.75pt;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="margin-left:1.253%;text-indent:0;font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase in tangible per share attributable to this offering</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	0.70</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:29.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">As adjusted net tangible book value per share as of March 31, 2025,</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">after giving effect to</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">this offering</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	1.77</font></p></td>
    </tr>
    <tr style="height:15.85pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilution in net tangible book value per share to investors participating in this offering</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:3pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	0.91</font></p></td>
    </tr>
   </table> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The above discussion and table is based on 66,525,854 shares of common stock outstanding as of March 31, 2025 and excludes as of that date:</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&middot; 877 shares of common stock issuable upon conversion of outstanding Series A Convertible Preferred Stock;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p> <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&middot; 10,823,072 shares of our common stock issuable upon exercise of outstanding stock options under our stock incentive plans at a weighted average exercise price of $3.80 per share;</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&middot; 2,807,353 shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $2.40 per share; and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p> <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&middot; 668,803 shares of common stock reserved for future grants and awards under our stock incentive plans.</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section28"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PLAN OF DISTRIBUTION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into a sales agreement with Jefferies, under which we may offer and sell up to $150 million of our shares of common stock from time to time through Jefferies acting as agent. Sales of our shares of common stock, if any, under this prospectus will be made by any method that is deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4)  under the Securities Act.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each time we wish to issue and sell shares of common stock under the sales agreement, we will notify Jefferies of the number of shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be made. Once we have so instructed Jefferies, unless Jefferies declines to accept the terms of such notice, Jefferies has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of Jefferies under the sales agreement to sell our shares of common stock are subject to a number of conditions that we must meet.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The settlement of sales of shares between us and Jefferies is generally anticipated to occur on the second trading day following the date on which the sale was made. Sales of our shares of common stock as contemplated in this prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Jefferies may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will pay Jefferies a commission equal to 3.0% of the aggregate gross proceeds we receive from each sale of our shares of common stock. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. In addition, we have agreed to reimburse Jefferies for certain ongoing disbursements of its legal counsel, unless we and Jefferies otherwise agree. We estimate that the total expenses for the offering, excluding any commissions or expense reimbursement payable to Jefferies under the terms of the sales agreement, will be approximately $35,000. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale of such shares.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jefferies will provide written confirmation to us before the open on The Nasdaq Capital Market on the day following each day on which our shares of common stock are sold under the sales agreement. Each confirmation will include the number of shares sold on that day, the aggregate gross proceeds of such sales and the proceeds to us.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the sale of our shares of common stock on our behalf, Jefferies will be deemed to be an &#x201c;underwriter&#x201d; within the meaning of the Securities Act, and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have agreed to indemnify Jefferies against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to contribute to payments Jefferies may be required to make in respect of such liabilities.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The offering of our shares of common stock pursuant to the sales agreement will terminate upon the earlier of (i) the sale of all shares of common stock subject to the sales agreement and (ii) the termination of the sales agreement as permitted therein.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This summary of the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions. A copy of the sales agreement is filed as an exhibit to the registration statement of which this prospectus forms a part.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jefferies and its affiliates may in the future provide various investment banking, commercial banking, financial advisory and other financial services for us and our affiliates, for which services they may in the future receive customary fees. In the course of its business, Jefferies may actively trade our securities for its own account or for the accounts of customers, and, accordingly, Jefferies may at any time hold long or short positions in such securities.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Jefferies, and Jefferies may distribute the prospectus supplement and the accompanying prospectus electronically.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section29"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEGAL MATTERS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The validity of the securities offered hereby will be passed upon for us by Sheppard, Mullin, Richter &amp; Hampton, New York, New York. Jefferies LLC is being represented in connection with this offering by Latham &amp; Watkins LLP, New York, New York.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section30"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXPERTS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements of Cardiff Oncology, Inc. as of December 31, 2024 and 2023 and for the years then ended incorporated by reference in this prospectus and in the registration statement have been so incorporated in reliance on the report of BDO USA, P.C., an independent registered public accounting firm given on the authority of said firm as experts in auditing and accounting.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section31"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHERE YOU CAN FIND MORE INFORMATION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus constitutes a part of the registration statement on Form S-3 that we have filed with the SEC under the Securities Act. As permitted by the SEC&#x2019;s rules, this prospectus and any accompanying prospectus, which forms a part of the registration statement, do not contain all of the information that is included in the registration statement. You will find additional information about us in the registration statement. Any statement made in this prospectus or any accompanying prospectus concerning legal documents are not necessarily complete and you should read the documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document or matter.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the reporting requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC&#x2019;s website at</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> http://www.sec.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We also maintain a website at</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> www.cardiffoncology.com</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing or telephoning us at: 11055 Flintkote Avenue, San Diego, California, 92121, (858) 952-7570.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section32"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INCORPORATION OF DOCUMENTS BY REFERENCE</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The SEC permits us to &#x201c;incorporate by reference&#x201d; the information contained in documents we file with the SEC, which means that we can disclose important information to you by referring you to those documents rather than by including them in this prospectus. Information that is incorporated by reference is considered to be part of this prospectus and you should read it with the same care that you read this prospectus and the accompanying prospectus. Information that we file later with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus, and will be considered to be a part of this prospectus from the date those documents are filed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We incorporate by reference the documents listed below, all filings filed by us pursuant to the Exchange Act after the date of the registration statement of which this prospectus and the accompanying prospectus forms a part, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the time that all securities covered by this prospectus have been sold; provided, however, that we are not incorporating any information furnished under either Item 2.02 or Item 7.01 of any current report on Form 8-K:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000095017025028992/crdf-20241231.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 27, 2025</font></a><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p> <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our Quarterly Report on Form 10-Q for the three months ended March 31, 2025 filed with the SEC on </font><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000095017025066886/crdf-20250331.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 8, 2025</font></a><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our Current Report on Form 8-K filed with the SEC on </font><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000095017025002076/crdf-20250103.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 6, 2025</font></a><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000095017025060074/crdf-20250429.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our definitive proxy statement filed with the SEC on April 29, 2025</font></a><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; and</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000110465912039425/a12-9768_98a12b.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on May 23, 2012, including any amendments or reports filed with the SEC for the purposes of updating such description</font></a><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div> <br> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any statements made in a document incorporated by reference in this prospectus are deemed to be modified or superseded for purposes of this prospectus to the extent that a statement in this prospectus or in any other subsequently filed document, which is also incorporated by reference, modifies or supersedes the statement. Any statement made in this prospectus is deemed to be modified or superseded to the extent a statement in any subsequently filed document, which is incorporated by reference in this prospectus, modifies or supersedes such statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information relating to us contained in this prospectus should be read together with the information in the documents incorporated by reference. In addition, certain information, including financial information, contained in this prospectus, the accompanying prospectus or incorporated by reference in this prospectus and the accompanying prospectus should be read in conjunction with documents we have filed with the SEC.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will provide to each person, including any beneficial holder, to whom a prospectus is delivered, at no cost, upon written or oral request, a copy of any or all of the information that has been incorporated by reference in the prospectus but not delivered with the prospectus. Requests for documents should be by writing to or telephoning us at the following address: Cardiff Oncology, Inc., 11055 Flintkote Avenue, San Diego, CA 92121; (858) 952-7570. Exhibits to these filings will not be sent unless those exhibits have been specifically incorporated by reference in such filings.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section33">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83777979_3.jpg" alt="img83777979_3.jpg" style="width:200px;height:53px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Up to $150,000,000</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares of Common Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">________________</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PROSPECTUS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">________________</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jefferies</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                      , 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INFORMATION NOT REQUIRED IN PROSPECTUS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14.  Other Expenses of Issuance and Distribution.</font></p><p style="text-indent:7.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:7.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth an estimate of the fees and expenses relating to the issuance and distribution of the securities being registered hereby, other than underwriting discounts and commissions, all of which shall be borne by the registrant.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:7.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of such fees and expenses are estimated:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:85.24%;box-sizing:content-box;"></td>
     <td style="width:2.1%;box-sizing:content-box;"></td>
     <td style="width:12.66%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</font></p></td>
    </tr>
    <tr style="height:14.4pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SEC registration fee</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;61,240</font></p></td>
    </tr>
    <tr style="height:14.4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounting fees and expenses</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">**</font></p></td>
    </tr>
    <tr style="height:14.4pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal fees and expenses</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">**</font></p></td>
    </tr>
    <tr style="height:14.4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Miscellaneous fees and expenses</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">**</font></p></td>
    </tr>
    <tr style="height:14.4pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total expenses</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:3pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:3pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">**</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">**	These fees and expenses depend on the securities offered and the number of issuances and accordingly cannot be estimated at this time.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15.  Indemnification of Directors and Officers.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:7.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 102 of the General Corporation Law of the State of Delaware (the &#x201c;DGCL&#x201d;) permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our amended and restated certificate of incorporation, as amended, provides that no director of the Company shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#x2019; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation, as amended, and bylaws will provide indemnification for our directors and officers to the fullest extent permitted by the DGCL. We will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending  action by or in the right of us by reason of the fact that this person is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#x201c;Indemnitee&#x201d;), or by reason of any action alleged to have been taken or omitted</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in such capacity, against all expenses (including attorneys&#x2019; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, the person had no reasonable cause to believe their conduct was unlawful. Our amended and restated certificate of incorporation, as amended, and bylaws provide that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#x2019; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner they reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, they are entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, they will be indemnified by us against all expenses (including attorneys&#x2019; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into separate indemnification agreements with each of our directors and executive officers. Each indemnification agreement provides, among other things, for indemnification to the fullest extent permitted by law and our amended and restated certificate of incorporation, as amended, and bylaws against any and all expenses, judgments, fines, penalties and amounts paid in settlement of any claim. The indemnification agreements will provide for the advancement or payment of all expenses to the indemnitee and for the reimbursement to us if it is found that such indemnitee is not entitled to such indemnification under applicable law and our amended and restated certificate of incorporation and amended and restated bylaws.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16.  Exhibits.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="border-spacing:0;table-layout:auto;width:96.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:15.26%;box-sizing:content-box;"></td>
     <td style="width:2.6%;box-sizing:content-box;"></td>
     <td style="width:82.14%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:24.5pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1*</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Underwriting Agreement.</font></p></td>
    </tr>
    <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:29.5pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000162828021004640/a12ex031221.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Open Market Sale Agreement&#x2120;, dated as of March 12, 2021, between the Company and Jefferies LLC (incorporated by reference to Exhibit 1.2 to the Company&#x2019;s Form S-3ASR filed on March 12, 2021)</font></a></p></td>
    </tr>
    <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:24.5pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000110465911066179/a11-28276_1ex3d1.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation. (incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Form 10-12G filed on November 25, 2011).</font></a></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:96.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:15.26%;box-sizing:content-box;"></td>
     <td style="width:2.6%;box-sizing:content-box;"></td>
     <td style="width:82.14%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:35.3pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000110465912019409/a12-6668_1def14a.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Appendix B to the Company&#x2019;s Proxy Statement on Schedule 14A filed on March 20, 2012).</font></a></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:36pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000095017025002076/crdf-ex3_1.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-kerning:none;min-width:fit-content;">Amended and Restated</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-kerning:none;min-width:fit-content;">By-Laws  (incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Form 8-K filed on January 6, 2025).</font></a></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:24.5pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000119312518190679/d601889dex31.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 12, 2018).</font></a></p></td>
    </tr>
    <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:24.5pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000119312519021144/d692543dex31.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on January 29, 2019).</font></a></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:35.3pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000119312519024055/d647432dex31.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on January 31, 2019).</font></a></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:35.3pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000119312519044909/d711195dex31.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Form 8-K filed on February 20, 2019).</font></a></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000162828020006555/trov050620ex31.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Trovagene, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Form 8-K filed on May 6, 2020).</font></a></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:25.9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.10</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000162828020009534/a31crdf061620.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on Jun 16, 2020).</font></a></p></td>
    </tr>
    <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:24.5pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000110465911066179/a11-28276_1ex4d1.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company&#x2019;s Form 10-12G filed on November 25, 2011).</font></a></p></td>
    </tr>
    <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2*</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Certificate of Designation with respect to Preferred Stock</font></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.85pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3#</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000095017025029044/crdf-ex4_3.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Senior Indenture</font></a></p></td>
    </tr>
    <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4#</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000095017025029044/crdf-ex4_4.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Subordinated Indenture</font></a></p></td>
    </tr>
    <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5*</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Senior Note</font></p></td>
    </tr>
    <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6*</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Subordinated Note</font></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7*</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Warrant</font></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8*</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Warrant Agreement</font></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9*</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Unit Agreement</font></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1#</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000095017025029044/crdf-ex5_1.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Opinion of Sheppard Mullin Richter &amp; Hampton LLP</font></a></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:96.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:15.26%;box-sizing:content-box;"></td>
     <td style="width:2.6%;box-sizing:content-box;"></td>
     <td style="width:82.14%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1**</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="crdf-ex23_1.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of BDO USA, P.C.</font></a></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.2#</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000095017025029044/crdf-ex5_1.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Sheppard Mullin Richter &amp; Hampton LLP (included in Exhibit 5.1)</font></a></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1**</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section35"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (included on signature page hereto)</font></a></p></td>
    </tr>
    <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.1*</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statement of Eligibility of Trustee on Form T-1 under the Trust Indenture Act of 1939, as amended</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107#</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000095017025029044/crdf-exfiling_fees.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Filing Fee Table</font></a></p></td>
    </tr>
   </table> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*</font><font style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">        </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent applicable, to be filed by an amendment or as an exhibit to a document filed under the Securities Exchange Act of 1934, as amended, and incorporated by reference herein.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** Filed herewith.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Previously Filed.</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 17.  Undertakings.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) The undersigned Registrant hereby undertakes:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) to include any prospectus required by Section 10(a)(3) of the Securities Act;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#x201c;Calculation of Registration Fee&#x201d; table in the effective Registration Statement; and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement;.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(l)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6) That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#x2019;s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#x2019;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(7)  Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(8) To file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act of 1939 in accordance with the rules and regulations prescribed by the Securities and Exchange Commission under Section 305(b)(2) of the Trust Indenture Act of 1939.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section35"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p> <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on May 8, 2025.</font></p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:49.63%;box-sizing:content-box;"></td>
     <td style="width:5.279%;box-sizing:content-box;"></td>
     <td style="width:45.091%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CARDIFF ONCOLOGY, INC.</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mark Erlander</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Erlander</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p> <p style="text-indent:4.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:25.225%;box-sizing:content-box;"></td>
     <td style="width:4.101%;box-sizing:content-box;"></td>
     <td style="width:50.59%;box-sizing:content-box;"></td>
     <td style="width:3.521%;box-sizing:content-box;"></td>
     <td style="width:16.563%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.037in;"><p style="font-size:1pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:8pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mark Erlander</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 8, 2025</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Erlander</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 8, 2025</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James Levine</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman of the Board and Director</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 8, 2025</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rodney S. Markin</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 8, 2025</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James O. Armitage</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 8, 2025</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mani Mohindru</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 8, 2025</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gary W. Pace</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 8, 2025</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Renee Tannenbaum</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 8, 2025</font></p></td>
    </tr>
    <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">L&acirc;le White</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.59in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:25.225%;box-sizing:content-box;"></td>
     <td style="width:4.101%;box-sizing:content-box;"></td>
     <td style="width:50.59%;box-sizing:content-box;"></td>
     <td style="width:3.521%;box-sizing:content-box;"></td>
     <td style="width:16.563%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid;padding-right:0.037in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">* By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">/s/ Mark Erlander</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:36pt;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Erlander</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:36pt;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attorney-in-Fact</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:12pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table> </div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.19in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>crdf-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated February 27, 2025, relating to the financial statements of Cardiff Oncology, Inc. (the &#x201c;Company&#x201d;) appearing in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">We also consent to the reference to us under the caption &#x201c;Experts&#x201d; in the Prospectus.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">/s/ BDO USA, P.C.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">San Diego, California</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">May 8, 2025</font><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#685040;white-space:pre-wrap;font-size:6pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">BDO USA, P.C., a Virginia professional corporation, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#685040;white-space:pre-wrap;font-size:6pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">BDO is the brand name for the BDO network and for each of the BDO Member Firms.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img83777979_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83777979_0.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   =V@
M P $     0   '\     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ ![_V@ , P$
M A$#$0 _ /[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]#^_BBB
MB@ HHKY]_:#_ &D? /[.GAR+5_%AEN;V\+)INDVF//N&0?,W/"1KD;G/ R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_2_OXHHHH
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M7]GO]GG[1::!:W%Q:M!92BV:ZM[63R9;J^NB05@9^D:D @J"'8U_117\]/\
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M7\=?L<?%U[O33JT$?B.V\0++:1QV6X&9I;-))8+Z(H"/+Q'(&(*L#\Z_:?\
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MQ&_X+8_L!^"_A8_Q"\.>+/\ A)-0DM?-L?"^F6\Z:E),5RL4RRHJ6X!X=Y"
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M\$J_V0O#/@7XH>);#1]*T.R-O)?7()N=6U.4F>[>WMHPTTTDLKLP1%8JI .
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img83777979_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83777979_1.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &8 O # 2(  A$! Q$!_\0
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M<:AJ/Q4\,3VOB.RT>PUZ^THZ[;6GB>YG\Z&WU31)9M*O95U"?5]#TN32=/\
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MMKN/P^/$,GG75JL5SYKK*7@]VNOVX?VY_CW^UOX4^ 7[,I^#7PVT3XA_L?\
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M;75V8S8S6!32VT[^S(8+.+BOAC_P22_9!^$_PQ^-OPT\-Z;\1+Z7]H'P?=>
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M$>NP:K+#XH\<VXM=:C\.O%IEB-*TE(E'V&RE6]>V;EKB7I7U112&?G1\.O\
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MWJVAZQINJ:7J.GZAIM]-#/;$['3R/1/V&_AYX7\&^-?"OA/XH_M#>%M4\?\
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MHO\ U_7H.U_S/D?XC_L=>"_B-=^"_$3?$[XZ^!OB1X.\$1_#B?XN_#;XB_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+?X=:]X9^*GA/Q->_#W7--GO-+U#3M>M6U2POO#^H6-[;ZC%&L*2S<G\7O\
M@I9\=Y?!?P;UKX,_LW:IIOC:3]NVV_9#^.OP\\9^-/AU-=:1XKT@Q3W/P\\-
M>)(==30KZY^(>G:GI][X;^)5K--X=\,K9W4>NV9>ZMC7V#I?_!/?X1V_A;2_
M#7B/X@?'/X@SZ9\;_A?\?E\3^._B%;ZMXAN/&OP@N(Y_!=BRV7A[2_#UAX7M
MQ$D6IZ-HF@:4VL#?<W]Y-?RRWCS^,?\ @GQ\$/&/A#X@>$WU[XJ^&[CQ]^U
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MN64I5\4M?9*J_=]HYIQ7/"4)1C.-2G.#C=*_T]_PC7[0W_1P?AC_ ,,+9?\
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MA;+_ .>=7SI\;_VK+[4?@-^S9X^_9DU71[[5OVO_ (J?!#P'\(_%WBC17O\
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M .%GXW_^:>CEH?\ /RM_X(A_\T>O]/0YL3_SZH?^%%3_ .9O7^GI[']EN?\
MGWG_ ._,G_Q-'V6Y_P"?>?\ [\R?_$UXY_PRO^SK_P!"6O\ X6?C?_YIZ/\
MAE?]G7_H2U_\+/QO_P#-/1RT/^?E;_P1#_YH]?Z>AS8G_GU0_P#"BI_\S>O]
M/35^+?P?TSXR>$&\'Z[K7Q+\)0IJNFZYI_B3X6>.O%'PU\9Z/JVDS&:SN].\
M2>&;JUNMF'EAN+"_CO\ 3+J&9_/LGF2WFA^:+_\ X)R_L]7/AKPYX=TN+XS>
M$;O1K+QAI/B#QOX)^,7Q!\,?$GXJZ+\1==_X2CXB:-\8_'-AJ(UKXC6'C?Q(
M6UK6QK4IN8KQW_L>YTN!VA/T%_PRO^SK_P!"6O\ X6?C?_YIZ/\ AE?]G7_H
M2U_\+/QO_P#-/6U/$.E%1IXK%4XJ3FHPIQ24FN5NRQ&NC:UTU?=F%7#>VDYU
ML'A*DG%0<IU92?*I1G:[PVW-%/SY8_+R/QO^PI\%/%NIZ3K'AY/BO\$]1T[P
M7X>^&VH3_L]?$_QG\&T\7?#OPC;267A7P9XUMO"MW#:^(]*\-6$USIVAWEU"
MFO:=IUU/8P:PMJ8XHOJG0?#4'AK0]&\.:1::E'I.@:78:-I<=_>ZMK-['I^F
M6T5G91W>KZS<W^L:I<1V\,:2ZAJE]>ZA=LIFN[J>=WD;S+_AE?\ 9U_Z$M?_
M  L_&_\ \T]'_#*_[.O_ $):_P#A9^-__FGJ9U8U8QC4Q.)G&'PJ5.,K7LNN
M([:*^R22LMJIT94I2G2PN%IRG;G<*LHWMZ85>;TM=ZO5W7L?V6Y_Y]Y_^_,G
M_P 31]EN?^?>?_OS)_\ $UXY_P ,K_LZ_P#0EK_X6?C?_P":>C_AE?\ 9U_Z
M$M?_  L_&_\ \T]9\M#_ )^5O_!$/_FCU_IZ:\V)_P"?5#_PHJ?_ #-Z_P!/
M3V/[+<_\^\__ 'YD_P#B:/LMS_S[S_\ ?F3_ .)KQS_AE?\ 9U_Z$M?_  L_
M&_\ \T]'_#*_[.O_ $):_P#A9^-__FGHY:'_ #\K?^"(?_-'K_3T.;$_\^J'
M_A14_P#F;U_IZ>Q_9;G_ )]Y_P#OS)_\31]EN?\ GWG_ ._,G_Q->.?\,K_L
MZ_\ 0EK_ .%GXW_^:>C_ (97_9U_Z$M?_"S\;_\ S3T<M#_GY6_\$0_^:/7^
MGH<V)_Y]4/\ PHJ?_,WK_3T]C^RW/_/O/_WYD_\ B:/LMS_S[S_]^9/_ (FO
M'/\ AE?]G7_H2U_\+/QO_P#-/1_PRO\ LZ_]"6O_ (6?C?\ ^:>CEH?\_*W_
M ((A_P#-'K_3T.;$_P#/JA_X45/_ )F]?Z>GL?V6Y_Y]Y_\ OS)_\31]EN?^
M?>?_ +\R?_$UXY_PRO\ LZ_]"6O_ (6?C?\ ^:>C_AE?]G7_ *$M?_"S\;__
M #3T<M#_ )^5O_!$/_FCU_IZ'-B?^?5#_P **G_S-Z_T]/8_LMS_ ,^\_P#W
MYD_^)K8TF*6,S^9')'D1XWHR9P7SC<!G&1G'3(KP3_AE?]G7_H2U_P#"S\;_
M /S3UZ+\/?A+\-OAI-JL_@+0QI$VL1VD6IL-;UW5_/CLVN'M5VZSJNHK!Y;7
M$YW6ZQ-)OQ(7"(%F2I)/EG4<NBE2C%/:]Y*M)K2_V7>R6E[JHNNVN>G2C'JX
MUIR:TZ1="">NGQ+37R/3Z***S-0K"U6&62:,QQ22 18)1&8 [VX)4'!K=KR;
MQ[\*_A7\4-0MI/'&C)K6H>'H6M+?_B>:_I#6<6H".Z,;)H^JZ;%/YP1)%>99
MF0 JC("RFH\K:YW*,>KC%2?RBY03_P# D3)R2]Q1E+2RE)P3[^\HS>BNU[KO
M:VFZZC[+<_\ /O/_ -^9/_B:/LMS_P ^\_\ WYD_^)KQS_AE?]G7_H2U_P#"
MS\;_ /S3T?\ #*_[.O\ T):_^%GXW_\ FGK3EH?\_*W_ ((A_P#-'K_3TRYL
M3_SZH?\ A14_^9O7^GI[']EN?^?>?_OS)_\ $T?9;G_GWG_[\R?_ !->.?\
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MTOM8TF>WU..[35!#!I"6D$<%M'[[_P ,K_LZ_P#0EK_X6?C?_P":>C_AE?\
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M\T>O]/3NYL3_ ,^J'_A14_\ F;U_IZ>Q_9;G_GWG_P"_,G_Q-'V6Y_Y]Y_\
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M[3BBT;1;>WU2&'2[5$]L_P"&5_V=?^A+7_PL_&__ ,T]'_#*_P"SK_T):_\
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M0C!.4K?6:K?-.3G.3<L.VW*<I2;;NV[]=/8_LMS_ ,^\_P#WYD_^)H^RW/\
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MK<5K5DZ1]W5?^QB\0?\ IUN*UJ!1V7HOR"BBB@84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !6WHW6X^D7\Y*Q*V]&ZW'TB
M_G)0!ML2",#CG)R,CT."#QZGMUZ=74UB,C)(YXQCGO\ 4].G?T/%.H *\_D_
MY&#Q'_UTTC_TVBO0*\_D_P"1@\1_]=-(_P#3:*!/>/K^C+%%%% PHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M V;?_D$W?UE_] CK&K9M_P#D$W?UE_\ 0(ZQJ "BBB@ HHHH **** "BBB@
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M@#9M_P#D$W?UE_\ 0(ZQJV;?_D$W?UE_] CK&H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "KNG?\?L'U?_
M -%O5*KNG?\ '[!]7_\ 1;T =77XZ?M*>"-#UKXB_%'Q+HGA?QO'X1\+?$_3
MY_CO\:K/0OA?K\?A&P\3_#KX4:=XG\,^&?#OB2^L_&FK-X6T;P]X \<1^/-'
M2XO_ (<:E=7\OAC2O$TUE>:7;?KCXCT5?$F@:SX??4]:T5-:TR]TQM7\.:E-
MH^OZ8M[ ]N;[1M6MP9]-U.V#^=97L0,EM.B2H"RBOS!\=?"/]CWP?X[UGP;X
M_P#VF_VA;CQAKVO^ -8\9^$9_C?\3O$,.LZSI$FDS^!X_&^D:!9WVF)Y]MI^
MC1FPUE+1-:T.WTZ+5H;W2HK/8?U_7YB?3U[V^[K=_E?5'ZK.ZQHSN<*BL['!
M.%4$DX ). #P 2>@!->7:+\;/A;X@U?3- TGQCI]QKFKW&J6=GI$MOJ-EJ*W
MFCM<K?V5_:7UE;3Z3>K]CO'MK/54LKF_BM+F;3XKJ*"5T]0D3S(WCWNF]&3?
M&VV1-RE=Z-@[77.5;!PP!P:\ \'_ +-G@3P=?^'-5BU?QOX@U/PZ^I2M?>)_
M$TNIW'B*>_O-<O[:Z\7&*UM$\1WNBW7B?Q')H][J"27<)UJ\^US7I6T-L#.N
MT*XM[B#4IK>XM[B%]?U^1)K>>*>%HSJESAUEB=T*'!^8-C@C.0<;6], [TPW
MW3O7#>RG/S'V7-<7X*\)^%O"VC7F@>&?#>A^'M#L]7\06%IHVBZ79Z9IEM9#
M5[QQ:06-I%%;Q6V^65_)2-4WRR-C+$UU7]GV&VV3[%:[+)B]FGD1[;1R<[K=
M=N(FSW0 T"6R]$6MZ9(WIE1EAN7*CU89RHQSEL#'/2C>F =Z8;A3O7#'T4YP
MQ]ESSQ5?[#9>9<R_9+;S+Q/+NY/)3?=)C 2X;&95 )&')&.*8=-TXQVT1L;0
MQ6;%[2,P1E+5R<[[=2N(FSSN3!SS0,M[TR1O3*C+#<N5'JPSE1CG+8&.>E&]
M, [TPWW3O7#>RG/S'V7-5_L-EON)/LEMYEXACNW\E-]U&1@I<-C,JXXVN2,<
M4W^SM/V6\7V&T\NS?S+2/R(]EM)G.^!=N(F!Y!0 YH M;ER1O7*\L-RY4>K#
M.5'?)QQS1O3 .],-PIWKACZ*<X8^RYYXJN+*S$EQ*+6W$MVFRZD\I-]RF,;)
MVQF1<<8;(Q3/[-TX1V\/V&T\JS8O:1^1'LM7)W;[==N(FSSN3!SR>: +>Y,D
M;TRO+#<N5'JPSE1[D 4;TP#O3#<*=ZX8^BG.&/L,FJ_V&R\RXE^R6XENT\NZ
MD\E-]S'C&R=L9E7'&U\C'%,.FZ>8[>(V-H8K1_,M8S!&4MGSG? I7$;Y_B4
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M[D >])YD> WF1[2<!MZ[6/HIS@GV!)Z\5!]CM!--<_98/M%S'Y-Q/Y2>;/$
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M>F6^Z-RY;_=&?F_X#FJO]G6&+I?L5KMOCF]7R(\79YYN!MQ*>3R^3WZ\U5U
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MAJ,GZE5^1'Q>\'Z9XS^.?QH\/6VC? ?4O&6M>/\ X='2/CG\0OB+:^$OB_\
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M<^W?%.IK'!!^OX]./J>WTYIU !7G\G_(P>(_^NFD?^FT5Z!7G\G_ ",'B/\
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M'+?7%Q=2H&2%9KNZNIKEX+6-VBL[9I3!:Q,R01H'?=U/_"-Z!_T"K;_OJ?\
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M / ]?Z>FY@^A_(T8/H?R-8?_  C>@?\ 0*MO^^I__CU'_"-Z!_T"K;_OJ?\
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M>9K::WU&P<B]T^\LKN"^L;VV^T&>W>6UO+:";RKB&6"=4:&9&C=A0&O9??\
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M@5;?]]3_ /QZO;/-U\OO_P"!Z_T]-S!]#^1HP?0_D:P_^$;T#_H%6W_?4_\
M\>H_X1O0/^@5;?\ ?4__ ,>H#7R^_P#X'K_3TW,'T/Y&C!]#^1K#_P"$;T#_
M *!5M_WU/_\ 'J/^$;T#_H%6W_?4_P#\>H#7R^__ ('K_3TW,'T/Y&C!]#^1
MK#_X1O0/^@5;?]]3_P#QZC_A&] _Z!5M_P!]3_\ QZ@-?+[_ /@>O]/3<P?0
M_D:,'T/Y&L/_ (1O0/\ H%6W_?4__P >H_X1O0/^@5;?]]3_ /QZ@-?+[_\
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M:?XR\5:?XUNGO/"FG64MGII_7]?T@>WS5O6^_P M_D?L/1110,\QTC[NJ_\
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M*V%5-U>1X;$8B%6@U5@Z&-H3JX#&1YI8/%8B$927I=%%%?2'G!1110 4444
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M-*B!/^M+[:^?];:GW/1110,\QTC[NJ_]C%X@_P#3K<5K5DZ1]W5?^QB\0?\
MIUN*UJ!1V7HOR"N(^(?@/3/B+X9G\/W]S<Z7>PW-MJ_AKQ)I^T:OX2\4::S2
MZ-XDTB1@0+K3YR1-;OFWU&PEN]-NTDM;N5#V]%5"<J<XS@W&<&I1DMTT[I]O
MD]'L]#+$8>ABZ%;#8FG&K0KTY4JM.5[3A-6DKIJ2=M5*+4HNTHM22:_)C7_"
M^N^&=5NM;L[V'X:^,_AKJT<>LZEHT$AT_P"%>NZ[([67BNSLF0_VY^S)\8#F
M?5-)N%DM_AWK]QJ%NPM].@G?3ON?X-_&NU^)L6H^"?&VCVOA+XLZ!:%/%_@:
MY=;G3=7L<+&?$_A">?<FO>$M2#I+\OG7&EF=+:_4H]O=7&S\6_ .J:XEAXY\
M$6NGS_$?PC8W]I9:;J2Q_P!C_$+PAJ.&\2?##Q0LH:&;2?$,*E])N;E)%T7Q
M EI?JOD/>QS?&.I^%= NM/\ !GB#PYK.K>&O"<FJ&V^#OQ$G<V?BGX"^/X;E
M[&]^"?Q&NKGS9(/#G]IB;1/#=YK:S6>G2EO"&M_:=%N](G/+CL).DZV;Y;AY
M8BAB9SGGF2T(\]2M5G%NMF6546[2S&<(SJXK -J&>T857!K.Z$JV:_%X&IBL
MAQJRO$XB,*5.$'E688F:I8>I@X3ITJ&$S&LDHX>AAYSHX.GF48J.08BKA(8F
M$>%\PP=#A3[.\81ZE\)?#'B+QEX.#:AH'A_3+S6-0^'][).]D\4 #ROX:U!$
MN+O0BA8S3V;17>EB!)I(X+8KFL;X ?&F]^,VD^([K4= M=&O/#FHV5G)/I5U
M<7NC7\>I6TUU MM/<JLR7UHD.+VW9I%\J>SND,:W(A1OPB^,=WXJU"Z^&WQ)
MTVW\+_%K1HKB.ZTS88=(\;6-H!'=:WX72=F/FHC(^N^&7:6[TGSEG@:^T:>V
MOF]VL=+T[1[<66EZ98:3:"1Y19Z;8VVGVPEE.Z2;[-:10P^9*<%Y-FY\#+$
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MXH T*7!]#53['%Y\]QYESON8O)D7[5/Y*IC&Z"#?Y5O+_P!-8523)/S>D/\
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M(/\ TZW%:U9.D?=U7_L8O$'_ *=;BM:@4=EZ+\@HHHH&%%%% !1110 4444
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MZK_V,7B#_P!.MQ6M63I'W=5_[&+Q!_Z=;BM:@4=EZ+\@HHHH&%%%% !1110
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M%'9>B_(****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWX=?LY_''PIX'^,FK7ES+<06$_QK^)?B?1M;N$OK:8Z=?GPQ#J5JEK9S)#U
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M[%47<X5(HXXT550"NVHHH **** "BBB@#YZN7^ _C#]HQ-&?7;.^^/\ \*_
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M!^R@)?BEI_AVZ^'_ ,8_"_A7PU\1?VZ-7\1ZK:^-OB)X?TO6H_B7XX\,Z_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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'1U)10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img83777979_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83777979_2.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   =V@
M P $     0   '\     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ ![_V@ , P$
M A$#$0 _ /[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]#^_BBB
MB@ HHKY]_:#_ &D? /[.GAR+5_%AEN;V\+)INDVF//N&0?,W/"1KD;G/ R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_2_OXHHHH
M*_#;]L2\E^&7[<>B_$KQ!#+_ &:&T?4TD12?,AM&$<P7U9"N2.O(]:_<FO&/
MC;\!?AW\??#2^'/'EJS- S26-_;G9<VDC#!:-\'@_P 2L"K<9' Q\=QQP]6S
M'!*GAY)3A)3C?:\>C^\_3/"?C/#9)FCKXV#E2J0E3G;=1E;5>C2^5^IWW@[Q
MKX2^(&@P^)?!6H6NIV$P_=W-I('7..5;'*L.ZL 1W%=37X1^,?V=?VGOV-M<
MF\=_!_4;O4]&7]Y/<Z<A;]VO\-]8G<& '5U# =<K7UC\"O\ @H_\._&-NFC_
M !B1/#FI*F/MR;Y-.G(ZD'#/"3_=?*_[7:O(RGQ#IJK]3S>G]7J_WOA?G&6W
MWZ=FSZ+B'P8KO#O,^'*ZQN'?\O\ $CY2AO?T5^KBD?I77$^/_B-X)^%_AV7Q
M3X\U&VTVRB!_>7#@-(P&0D:?>=SV502?2OST^/'_  4C\'^&XY/#WP/A77-0
M8;/[6N%=+"%CP/+0[7G8=ONKGNW2OF_P'^RE^T?^U;KT?Q#^.^IWVF:9+^\B
MFU$?Z4\3<[;2SX6!".C,JCOM:IS3Q"C.J\'DU+ZQ5\O@CYN6WW:>:9ID'@S.
MEAUF?$]=8/#]I?Q)^48;I^JNM^5HT_\ @GM!?>,OVG/%'Q#T^!TL!:W]S*[C
M_5G4;L20QD]-Q 8X_P!DU[1K&M:=X"_;(GU_Q8YM+2+4VFDF=20L<]L51\ $
M[26&2!QSZ4W7?VO?V.?V'M)/PJ^&L=SKVHQ39U*/1F2=S.ORLUW>2%8S)QC8
MA;;TVJ*Z/PA\<?V3/V[TCTNTNI]"\6I%Y=O:Z@$M[X@<XC^9HKI 23M#%AR<
M+7Q'&/@GGM3A_ SP*3Q&&K+$)2OR2DKOEOHTMM=$^ZO=>?B?I(<+X_BS%T95
M^6G5I>P237.EHK]4Y;^ZFVNS:U_2;2]5TS6["/5-'N(;JVF7?%/;N)(W'J&4
MD&OG;]J/QWX2T+X6:OX8U*^A34=2LS!9V2G=,Y9AR5&2J_[1P/QKY&F^$G[3
MGP2U*?3_ (=37MY8W(*K-I95XVW?Q-!)GRY!_> ^C5W'PV_8]U_Q)>_\)9\:
M[R??,_FR6"2F2YE/_3>?)QGT4D_[0KY3-O$OB?/,'5R#"9!.EB*D90J2J:48
M*2LY1G]JZ;:M\N<]3 <%Y)EF(AFN(S:,Z,&I04-:DFG=)Q^SY_CRGJ?[$5O/
M%\)KN:1&5)=:G:-B.&"Q1*2/8,"/J*^QJRM#T+1_#6DP:%H-O%:6=L@C@MX1
MA44>GUZDGDGDUC^.?'O@GX9>%[KQK\1-6T_1-(LD\R[U+5+A+:WB7_:DD*J,
M]AG)[5^^>'W#$LER7!Y5.?.Z4%%M;-];>5]O(_*N+,[CF698C'1CRJI)M+LN
ME_,ZVBOR+\6?\%Q_^"='A;5FTF'Q9J6K;&VM<Z1H][/;\=UD:) P]UR#VKZ2
M_9X_X*/_ +&/[4>N1^$_A!XVL+G6IE+0Z)J,4VG7TH49/E1721F4@<D1EB!S
M7V/*SYVZ/N*BBBD,**** "BBB@ HHKYB_:[_ &K_ (<_L8?!BX^.'Q1MM5O-
M,M[^TTT6NBQQ2W<DUX^Q BS2PI@<LV7' .,]*$@/IVBOD?X8_MJ?!KXC?LG)
M^V;?-J'ASP8;"\U.:77XXTNH;>RGDMV9X[:2<$N\9\M49F;*@#)Q69^R%^WI
M^SG^V_IFKWWP*U&]FFT&:*+5-/U6T>SNX4GW>3+L;(:.38VUE8X((8 \4[!<
M^RZ*X_Q_\0?!'PK\'W_Q ^(^JV.B:+ID!N+_ %/495A@AC'=F;N3@ #EB0 "
M2!7YM?#O_@LS^PK\5OC-I/P-\!ZUKE_JNNZG%H^E72Z/=)93W,S;4 D=5<*3
M_&T84#DD"A)L+GZJT5Y5\9?C?\)OV>_ UQ\2?C1KUAX>T6V98WO;]]H:1_NQ
MQ(H+RR-_"B*S'L.*^)_V>/\ @K1^QM^U'\9K3X$_"+4]<N]=OX[J:R^U:3<6
MUO*EI$TTI\QQ\H"*2-ZKGIU(%%@N?I;1112 **^#OV@_^"F7[$_[,>M3>%?B
MEXWL5UFW.+C1=(BFU.]A/I-':)((C[2%3[5X'X-_X+@?\$Z/%^III<WB^_T=
MG;:L^MZ1>V\&3_>E6)U4>[$ =S3LQ71^MM%<SX.\9^$?B%X;M/&/@34[#6-)
MOXA/9:EIDZ7-M,AZ,DD9*L/H>.E=-2&%%%% !1110 4444 %%%% !17G7Q>^
M*'AKX)_"SQ#\7O&7GG2O#6CW>MZ@MJH>9H+2)I76-69078+A06 )(R1UKYR_
M8E_;E^&'[=_@75_B%\*=*\0Z98:-JXT6<>(8;>&26X\B.<F(6]Q< JJR*"20
M<]N].P'VE1112 **** "BBB@ HHHH **** "BBB@ HHHH __T_[^**** "BB
MB@ (SP:^._B]^PU\!_B[J;:]<V<^BZC(2T]WH;);B8G^*6(JT;-_M!0Q[DU]
MB45YV9Y1A<;3]EBJ2G'LU?[NQ[61<1X_*ZWUC+\1*E+O%VOY/NO)GR;\&OV+
M?@;\%KY=<TBQEU34T(,6HZRRW$D)'>% JQQG_:"[O>OR)^.W[1_[37[;'QHU
M7]GO]GG[1::!:W%Q:M!92BV:ZM[63R9;J^NB05@9^D:D @J"'8U_117\]/\
MP2L_Y.\\=_\ 8&U+_P!.<-?2\'Y3A,!AZTL-1C'D2:5M+OKYOSW/QWQMXBS3
M.LPRW!8W&S:Q$I*;YO><8I/E3Z+5Z+3R/KK]FK_@E9\)_AI!%XA^-30^+M9*
M9^PNA72;9CU"Q'YIR/[TF!Z(.M>=?M*_\$G-!UJ6;QK^S/=KHNH*YN/^$>O)
M&%FS@Y'V6XY>W8'[H;<F>A05^T-%:QS_ !:J^U]IKVZ?<:5?"G(9X)8'ZHE%
M;-?'?OS;W];KRMH?AC^Q)^UY\=_!'QR@_9(_:7^U7,\DKZ;97.I$/J%E=K%Y
MT44LREA/#*@PCDL02I#%3Q^YU?SS_$[G_@L)IA_ZF+1O_3;'7]#%='$-*"E2
MJQC;GBF[;79Y7A-C,0Z..P5>JZBP]:5.+EK+E5K7?7^EM8\X^+_Q7\%? SX8
M:Y\7OB+="ST3P]ITVIZA/U;RXER$1?XI';"(O5F( ZU_(-X8T#]J;_@O'^TM
MJ&K^(-2G\+_#'PQ=*P@7,UII-O*3Y,$$652YU.=%+/*_"#)X38C?H/\ \'&G
MQFU+PO\  [P/\$],F:./Q3KESJVJ*A(\RUT:-/+C;U4SW"/@]T![5^E__!++
MX"Z3^SW^PWX$\-6D*1W^L:3%XIUR91AI;[5D6X;>>I,<;)"/14 KP5HKGZN]
M78\R^&O_  19_P"">'P]\/IH^H^"!XFN0@$VJ>)+VYN;F5L<G;')%"GTCC6O
MCS]I_P#X("?"7Q;KNF>,_P!D36Y_AWJ$&IV\M[9W,UQ>6<<*N"UQ9.7:X@N8
ML;HU\PHQXS'UK^AJBES,=D<]X2T.Y\,^%=-\.7M_>:K-86$%E+JFHE6NKMX8
MPC3SE%53)(1N<A0"Q/%= S*BEF(  R2>@%?!W_!03]O/X>?L%_!W_A.?$<0U
M37]4>2R\+^'4D$;WMRJ[FDE;!,=M""&E?!/*JOS,*_%[X4_L2_\ !0+_ (*A
MZ1#\=OVQ/B3K/@?PEK"B]\/^$M&1XC):2<QR)8B2.&")U.4DG\V>1<,PP02)
M=6#9_45;WEI> M:2QRA3AC&P;!]\59K^'3QM^S5JO[&G_!57P%^S1\$?&GBJ
MYBGU_P *SW%])=-:W!_M"Y5YX9!;%$>,Q+R"O(8@@]3^I/\ P<:_$O7_  K\
M)?AMX/\ #6H7VGW&I>(M1U*1K"XDMW:.QM!& 6B921NN <'C-/D%<_I!) Y-
M ((R.AK^6K5O _[:_P#P5L\/VGA_X+>+'\'_  =\&:=9^'K77-2GNXY?%NKV
M4$<5[>,L'[VXC6965#(P0=<-(6V_77QJ_: O_P#@C9_P3O\ "'PEOK^T\3_$
MBX@O--T6662::UDNGFDN;F_D$Q$IM[59E"H<;F*)P"2!PZ#N?NK/=6UMM^TR
M1Q[CM7>P7)]!GK7\^G_!QEXR72?V4O!W@M6PVL^.X[AUSUBL+*Y=OP#R)7R?
M\ _^"1W[3G[=OAB']IC]M/XG^)=(OO$<2ZEH^F(IN;Y+:8;X994D=(+1&4AH
M[>*/Y4(SL/RU^>/_  4_^ ?[2/[+_B#PA^RS\4?'LWC[PU''=ZSX$N;S?]LM
MDO7CM)H95E:1T >-=B"5X^I3;EE#C'4F3TV/ZF?V8_V6_!7Q3_X)6^"?V:_B
M+'.FE^(OASIZZ@UHPCN(I;Z-;WSHV(8"1)G#KD$9'((R*U?^"??_  33^%O_
M  3]M?$-SX0UK5?$6K>)&@CO=4U1(H=EK:ES#!%%"-JC=(S.Q)+''0 "O"O^
M"LFMWGP*_P""5]WX:\/7=S874=KX9\+V5Q92O!*OES6ZL$="K+^ZA;H>E<U_
MP2T^%_C3XL_\$F4\)7/BK7=(U?QN/$)@\41SRW&H6!N+J2VBFA=Y ^8UB!4!
MU]B.M(KJ?"G_  7!\<^-_CY^V)\+?V#O#-W<6^FWLVF7-Y!$Q"3ZCK=X;6&:
M1>CBU@1F3/0NYK^@7X)_L6?LM?L^:)I.D_#'P/X;L[C1D3[)K$FGV\VJ&95V
MM.]ZZ&<ROR6;>.IQ@<5_&7J7[*'Q5\2?\%2H_P!DQ?B?K6J>)+'5H]/C^)-T
M+E[^V:UT[[=O16NFF!AR8EQ<#!Y! XK^@3X?_P#!)?\ :7\,>$O%_ASQ#^TM
MXYOKGQ%I%KIVF:C&+U9-,D@O8;N251)J4F?.2'R6V-&P1V^8@D&FM-R4]3\\
M_P!O636_V^/^"Q/A?]C?7+NZ'A#PU>6NF3V=K(5"I]D&IZK<#J%FDBQ 'QE0
MJ^^?Z<?A9^S7^SY\$(K=/A'X*\,>'GM;;[)#=:7IT$-UY)QE6N GG/NQ\Q9R
M6/)R:_B4_98_9/\ B[^T+_P4(\6?!3PE\3=:TK7M GU[[;\1XQ<OJ%RFF3BR
M>1MMTDP^T$JIS.<*<$M7]9O[!'[&GQ7_ &1K+Q/%\5OBEKOQ-GUZ:Q:RFUG[
M2HT^.T64.D:W%W=<RM("Q4K]T YQ2EH$6?H77\Y'_!8G_@HY\1?#/C"V_84_
M9,GNCXPUIK:T\1ZGI!/VZ!M0VBVTRR93E+F<.K2R#YD1E"D%F*_T(^-?$]EX
M)\&ZMXSU(9M](TRZU2X [QVL32O^BFOY#?\ @B!X,N/VH_V]O&?[5/Q+Q?7V
MB6USXC0SC?\ \3?7IW1)!G/^IA$P3^[E2.@I174<GT/T8_8V_P""#7P!^'OA
M6S\5_M91OXW\6W<8N;[2S<2Q:-92R?,8E6)DDNG4GYY)6VLV<(!@U]3?&C_@
MB]^P)\6/"DVB:%X/@\&ZB8V%IK?A622VFADQ\I>%F:"9<\E70D]B.M?JU14\
MS'9'\7O[&7Q5^,W_  2<_P""@\W[)?Q7OVN/!^MZW;:/J<>YELG34BJZ=K5J
MC%A$Q+H)A_=WHV612/[0J_CY_P"#C31+/1OVE_AYXRTT*E]=^#YHIF3AS]@O
MBT+$CT,S 'VK[M_X+K_%WQ+X<_82\ Z/I>HWUCJ/B;Q#IDUW+9SO!+)%:Z?+
M/*"\95B/.:,D9QGZ5HU>Q*TN?T,U#%<V\[,L,B.4.'"L"5/H<=*_EJ^$'C']
MLC_@IY\+?"W[.G[//B35/ WPT\$^%M(T3Q[\1KMICJ6NZS%:1BXMK=ED2:1(
MSG*^:FX8>5L,B'X-_;"_9S^.?_!&WX[^"_B3\*?B%JFM1:LD^H6UY(LEH\TE
M@\?VJSOK<32QSPRK*O)/(8\ J#4\@W(_N-IKND:EW(  R23@ >IKYQ^*7[3W
MP]^#'[,UQ^U#\0G>UT:V\/6^NFW0@SS/=Q(T%K$#C=++(ZQH.FXY.!DU_,C\
M,/ W[>7_  6_\;:M\0O&7BVZ\!?"K3K][.VL[$RFS5Q\WV6UM8WA^VSQHR^=
M<3OM4G"_\\PE$;9_7Q!<V]U'YUM(DB$XW1L&'YBIJ_FB\)?\$=_VS?V1OC+X
M7\=?L<?%U[O33JT$?B.V\0++:1QV6X&9I;-))8+Z(H"/+Q'(&(*L#\Z_:?\
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MQ&_X+8_L!^"_A8_Q"\.>+/\ A)-0DM?-L?"^F6\Z:E),5RL4RRHJ6X!X=Y"
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M\$J_V0O#/@7XH>);#1]*T.R-O)?7()N=6U.4F>[>WMHPTTTDLKLP1%8JI .
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img83777979_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83777979_3.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   =V@
M P $     0   '\     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ ![_V@ , P$
M A$#$0 _ /[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]#^_BBB
MB@ HHKY]_:#_ &D? /[.GAR+5_%AEN;V\+)INDVF//N&0?,W/"1KD;G/ R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_2_OXHHHH
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M7]GO]GG[1::!:W%Q:M!92BV:ZM[63R9;J^NB05@9^D:D @J"'8U_117\]/\
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M7\=?L<?%U[O33JT$?B.V\0++:1QV6X&9I;-))8+Z(H"/+Q'(&(*L#\Z_:?\
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MQ&_X+8_L!^"_A8_Q"\.>+/\ A)-0DM?-L?"^F6\Z:E),5RL4RRHJ6X!X=Y"
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M\$J_V0O#/@7XH>);#1]*T.R-O)?7()N=6U.4F>[>WMHPTTTDLKLP1%8JI .
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
